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NOTES 
1. All the temperatures are expressed in degree centigrade (˚C). 
2. Melting points of all the compounds are uncorrected and have 
been recorded in open capillary method. 
3. Room temperature, wherever mentioned is normally correspondence to 28-
33˚C. 
4. Silica gel-G was used for preparing the TLC plates using appropriate solvent 
system. 
5. IR spectra were recorded in KBr pellets on SHIMADZU-FTIR 8400-S 
spectrometer. 
6. NMR spectra were recorded on BRUKER spectrophotometer (400 MHz) using 
TMS as an internal standard and CDCl3 and DMSO-d6 as solvent. 
7. Mass spectra were recorded on WATERS LCMS. 
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A brief summary of the work to include in the thesis entitled “STUDIES ON 
BIOLOGICAL EVALUATION OF NOVEL HETEROCYCLIC COMPOUNDS” is 
mentioned as under. 
PART-I : STUDIES ON PYRIDINES. 
PART-II : STUDIES ON PYRIMIDINES. 
PART-III : STUDIES ON TETRAHYDROTHIENO [2, 3-c] PYRIDINES. 
 
PART I: STUDIES ON PYRIDINES. 
Pyridines derivatives have recently received considerable attention due to their 
synthetic and pharmaceutical importance. The pyridine nucleus is an important 
heteroaromatic class of compounds with a wide range of pharmacological activities and it 
is present in many products such as drugs, foods, vitamins, flavorings, plants, dyes, 
rubber products, adhesehives, insecticides and herbicides. They also possess diverse 
biological activities viz, antibacterial, antitubercular, calcium channel blocker, 
cardiovascular, vasodilator, antihypertensive, anti-oxidant, anti-inflammatory, anti-HIV 
and anti-carcinogenic activity. 
The work is further subdivided in following sections 
SECTION I:  Preparation, Characterization and antimicrobial evaluation of  4-
(substituted amino) -3-nitro-N-[6-{4-oxo-3,4 dihydro-1’H- spiro-(chromene-2,4’- 
piperidin)-1’-yl}pyridine-3-yl]-benzamides. 
 
 
 
 
 
          
 
 
(Ia-k) 
R= Substituted amino 
4-(substituted amino) -3-nitro-N-[6-{4-oxo-3,4 dihydro-1’H- spiro-(chromene-
2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides (Ia-k) have been prepared by 
nucleophilic substitution of the chloro atom of  4-chloro 3-nitro- N-[6-{4-oxo-3,4 
dihydro-1’H- spiro-(chromene-2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides with 
different substituted amines. 
N
O
O
N
NH
O
R
N
+
O
-
O
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SECTION-II: Preparation, Characterization and antimicrobial evaluation of 4-
(substitutedphenoxy)-3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- Spiro-(chromene-2, 4’- 
piperidin)-1’-yl} pyridine-3-yl]-benzamides. 
N
O
O
N
NH
O
R
N
+
O
-
O
 
(IIa-k)  
R= Substitutedphenoxy 
 
4-(substitutedphenoxy) -3-nitro-N-[6-{4-oxo-3,4 dihydro-1’H- Spiro-(chromene-
2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides (IIa-k) have been prepared by 
nucleophilic substitution of the chloro atom of  4-chloro 3-nitro-N-[6-{4-oxo-3,4 dihydro-
1’H- spiro-(chromene-2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides with different 
substituted phenols. 
 
SECTION-III: Preparation, Characterization and antimicrobial evaluation of 4-
(substitutedthiophenoxy)-3-nitro-N-[6-{4-oxo-3,4 dihydro-1’H- Spiro-(chromene-
2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides. 
N
O
O
N
NH
O
R
N
+
O
-
O
 
                                                                     (IIIa-k) 
                R= Substituted thiophenoxy 
 
 4-(substitutedthiophenoxy) -3-nitro-N-[6-{4-oxo-3,4 dihydro-1’H- spiro- 
(chromene-2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides(IIIa-k) have been prepared 
by nucleophilic substitution of the chloro atom of  4-chloro 3-nitro-N-[6-{4-oxo-3,4 
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dihydro-1’H- spiro-(chromene-2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides with 
different substituted thiophenols. 
 
SECTION-IV: Preparation, Characterization and antimicrobial evaluation of 4-
(substituted phenyl)-3-nitro-N-[6-{4-oxo-3,4 dihydro-1’H- spiro-(chromene-2,4’- 
piperidin)-1’-yl}pyridine-3-yl]-benzamides. 
N
O
O
N
NH
O
R
N+
O-
O
 
(IVa-k) 
R= Substituted phenyl 
 
4-(substituted phenyl)-3-nitro-N-[6-{4-oxo-3,4 dihydro-1’H- spiro-(chromene-
2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides(IVa-k) have been prepared by using  4-
chloro 3-nitro -N-[6-{4-oxo-3,4 dihydro-1’H- spiro-(chromene-2,4’- piperidin)-1’-
yl}pyridine-3-yl]-benzamides using different substituted phenyl boronic acids. 
 
PART-II: STUDIES ON PYRIMIDINES. 
Pyrimidine derivatives represents one of the most active classes of compounds 
possessing a wide spectrum of biological activities viz significant in vitro activity against 
unrelated DNA and RNA viruses including polio and Herpes viruses, diuretics, 
antitubercular, antihypertensive some pyrimidine which occurs as natural products like 
nucleic acids and vitamin-B and and can be used as therapeutic agents for the treatment of 
AIDS and antitumor. In view of getting better therapeutic agents the new pyrimidine 
derivatives have been synthesized possessing 1,4,8-Triazaspiro and benzoylpiperazine 
moieties. 
 
SECTION-I: Preparation, Characterization and antimicrobial evaluation of Ethyl -
2-(4-Substituted benzoylpiperazin-1-yl)-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] 
dec-8-yl ) pyrimidine -5-carboxylate. 
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N
N
N
N
N
NH N
O
O
OCH3
O
R
 
 
(Ia-k) 
R= Aryl 
 
Ethyl 2-(4-Substituted benzoylpiperazin-1-yl)-4-(3-oxo-1phenyl-1,4,8-triazaspiro 
[4,5] dec-8-yl ) pyrimidine -5-carboxylate (Ia-k) have been prepared by using Ethyl 2-
(piperazin-1-yl) 4-(1-phenyl-3-oxo-1,4,8-triazaspiro [4,5] dec-8-yl ) pyrimidine -5-
carboxylate with different substituted benzoyl chlorides. 
 
SECTION-II :  Preparation, Characterization and antimicrobial evaluation of Ethyl 
-2-[4-(Substituted benzenesulfonyl) piperazin-1-yl]-4-(1-phenyl-3-oxo-1,4,8-
triazaspiro [4,5] dec-8-yl ) pyrimidine -5-carboxylates. 
 
N
N
N
N
N
NH N
O
O
OCH3
S
O
O
R
 
(IIa-k) 
R= aryl 
 
Ethyl 2-[4-(Substituted benzenesulfonyl) piperazin-1-yl] 4-(1-phenyl-3-oxo-1,4,8-
triazaspiro [4,5] dec-8-yl) pyrimidine -5-carboxylate (IIa-k) have been prepared by using 
Ethyl 2-(piperazin-1-yl) 4-(1-phenyl-3-oxo-1,4,8-triazaspiro [4,5] dec-8-yl ) pyrimidine -
5-carboxylate with different substituted phenyl sulfonyl chlorides. 
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PART-III: STUDIES ON TETRAHYDRO THIENO [2, 3-c] PYRIDINES. 
Thieno pyridine represents one of the most active classes of compounds 
possessing a wide spectrum of biological activities including prophylaxis or treatment of 
obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, 
metabolic syndrome and sarcopenia. In view of getting better therapeutic agents of thieno 
pyridine derivatives possessing sulfonamide moiety have been synthesized.    
 
SECTION-I: Preparation, Characterization and antimicrobial evaluation of 2-
(substitutedbenzylideneamino)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydro 
thieno [2, 3-c]pyridine-3-carboxamides. 
N
SS
CH3
O
O
NH2
N
O
R
 
(Ia-k) 
R= Aryl 
 
2-(substitutedbenzylideneamino)-6-[(4-methylphenyl)sulfonyl]-4,5,6,7 tetra hydrothieno 
[2,3-c]pyridine-3-carboxamide (Ia-k) have been prepared by using 2-(amino)-6-[(4-
methylphenyl)sulfonyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide with 
differently substituted aromatic aldehydes. 
 
SECTION-II: Preparation, Characterization and antimicrobial evaluation of 2-aryl-
7-[(4-methylphenyl)sulfonyl]-1,2,3,5,6,7,8heptahydropyrido[4',3':4,5]thieno [2,3-d] 
pyrimidin-4-ones. 
N
SS
CH3
O
O
N
H
N
H
O
R
 
(IIa-k) 
R= Aryl 
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2-aryl-7-[(4-methylphenyl)sulfonyl]-1,2,3,5,6,7,8heptahydropyrido[4',3':4,5] 
thieno [2,3-d]pyrimidin-4-ones(IIa-k) have been prepared by using 2-(amino)-6-[(4-
methylphenyl)sulfonyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide with 
different substituted aromatic aldehydes. 
 
SECTION-III: Preparation, Characterization and antimicrobial evaluation of Ethyl-
2-(3-arylureido)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydro thieno [2, 3-c] 
pyridine-carboxylates. 
N
SS
CH3
O
O NH
O
O
NH
O R
CH3
 
(IIIa-k) 
R= Substituted Phenyl 
 
Ethyl-2-(3-arylureido)-6-[(4-methylphenyl)sulfonyl]-4,5,6,7-tetrahydrothieno 
[2,3-c]pyridine-3-carboxylates (IIIa-k) have been prepared by using Ethyl 2-(phenoxy 
carbonylamino)-6-[(4-methylphenyl)sulfonyl]-4,5,6,7-tetrahydrothieno[2,3-c] pyridine-3-
carboxylate with differently substituted aromatic amines. 
CONSTITUTION OF PRODUCTS: 
The structures of the compounds have been characterized by elemental and spectral 
analyses. The purity was checked by TLC. 
 
ANTIMICROBIAL ACTIVITY: 
The synthesized compounds were tested for their antimicrobial effect using different 
strains of bacteria and fungi. 
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GENERAL INTRODUCTION 
 
The chemistry of the heterocyclic compounds is as logical as that of aliphatic or 
aromatic compounds. This study is of great interest both from the theoretical as well as 
practical point. A heterocyclic compound is one which possesses a cyclic structure with at 
least one different kind of atom other than carbon in the ring. The most common type, 
contain largely nitrogen, oxygen and sulphur heteroatoms, but many other elements, 
including even phosphorous, silicon can also serve. The heterocyclic compounds containing 
the less common atoms have been subjected to much investigation in recent years. 
The variety of heterocyclic compounds is enormous, their chemistry is complex and 
synthesizing them require great skill. Among large number of heterocycles found in nature, 
nitrogen heterocycles are most abundant than those containing oxygen or sulphur owing to 
their wide distribution in nucleic acid instant and involvement in almost every physiological 
process of plants and animals. 
Heterocyclic systems are encountered in many groups of organic compounds 
possessing great applicability in industry as well as in our life in various ways i. e. most of 
the sugars and their derivatives, including vitamin C, for instant, exist largely in the form of 
five membered (Furanoside str.) or six membered (Pyranoside str.) ring containing one 
oxygen atom. Most members of the vitamin B group possess heterocyclic rings containing 
nitrogen; one example is vitamin B6 (Pyridoxine), which is a derivative of the pyridine 
essential in amino acid metabolism. Many other examples of the important heterocyclic 
compounds in biological systems can be given. 
Natural products containing heterocyclic compounds such as alkaloids and glycosides 
have been used since old age, as remedial agents. Febrifuge alkaloid from ancient Chinese 
drug, Chang Shan, Reserpine from Indian rauwolfia, Curen alkaloid from arrow poison, 
Codenine, j-Tropine and Strychnine are all examples of heterocyclic compounds. Many 
antibiotics including penicillin, cephalosporin, norfloxacin, streptomycin etc. also contain 
heterocyclic ring systems. Majority of the large number of drugs being introduced in 
pharmacopeias in recent years are heterocyclic compounds. 
Many veterinary products like Pyrantel and Morantel are the drug of choice as broad 
spectrum anthelmintics. The herbicides Atrazine and Simazine are well known 
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anthiocyanins, chlorophyll has contributed much colour chemistry and many other 
heterocyclic colouring matters are in use since prehistoric times. The heterocyclic compound 
Tetraselena fulvalene was the first ionic molecular crystal to demonstrate superconductivity. 
The word drug is derived from the French word drogue which means a dry herb. 
According to WHO a drug may be defined as any substance or product which is used or 
intended to be used for modifying or exploring physiological system or pathological status 
for the benefit of recipient. 
There are two main divisions of medicinal chemistry. The first chemotherapy, 
concerns the treatment of infections, parasite or malignant disease by chemical agents, 
usually substances that show selective toxicity towards the pathogen. The other division 
relates to diseases of body disfunction and the agents employed are mainly compounds that 
effect the functioning of enzymes, the transmission of impulses or the action of hormones on 
receptors. Heterocyclic compounds are used for all these purposes; because they have a 
specific chemical reactivity. The introduction of heterocyclic group into drugs may effect 
their physical properties, for example the dissociation constants of sulpha drugs or modify 
their patterns of absorption, metabolism or toxicity. 
During the period of 1930-1950 there was an urgent need for new drug to treat 
disease which had a high mortality rate, there was only limited appreciation of the hazard 
such drugs might present, and toxicological studies before clinical trials were fairly 
rudimentary. Proving the proverb Necessity is the mother of invention, during the decade of 
30 and 40s a large number of drugs introduced. Therefore this period is regarded as Golden 
Period of new drug discovery.  
Heterocyclic compounds are obtainable by the following methods.  
a. Isolation from natural sources, i.e. alkaloids, amino acids, indigo dyes etc.  
b. Degradation of natural products i.e. acridine, furfural, indol, pyridine, quinoline, 
thiophene etc.  
c.  Synthesis: Synthesis methods for obtaining heterocyclic compounds may be divided 
into ring closer reactions, addition reaction and replacement reaction. Cyclisation is 
usually accomplished by elimination of some small molecules such as water or 
ammonia. 
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Heterocyclic compounds have a great applicability as drugs because, 
a. They have a specific chemical reactivity.  
b. They resemble essential metabolism and can provide false pythons in biosynthetic 
Process. 
The current interest in the creation of large, searchable libraries of organic compounds has 
captured an imagination of organic chemists and the drug discovery community. Efforts in 
numerous laboratories focused on the introduction of chemical diversity have been recently 
reviewed and pharmacologically interesting compounds have been identified for libraries of 
widely different compositions. 
Research in the field of pharmaceutical chemistry has its most important task in the 
development of new and better drugs and their successful introduction into clinical practice. 
Central to these efforts, accordingly stand the search for pharmaceutical substances and 
preparation which are new and original.  In addition to these objectives the searching for drug 
which exhibit a clear advantage over a drug already known. Such advantages may be 
qualitative or quantitative improvement in activity, the absence of undesirable side effect, a 
lower toxicity, improved stability and decreased cost. 
It is important at the outset to note that drug discovery is not an unambiguous term in 
the R and D world. For example, it can be defined using either programmatic or 
organizational approaches (or both), with several options on each category. Hence, it is 
important first to understand this variability and to adopt a specific definition for the purpose 
of this discussion. 
The contribution of organic chemistry for the development of scientific medicine in 
the 19th century mainly from acyclic and carbocyclic compounds, although the pyrazoline 
derivative antipyrin 1 was introduced as an antipyretic and analgesic in 1984 and the first 
barbiturate baritone (veranol) 2 in 1903. Guttmann treated, malaria with methylene blue in 
1891, with slight success, and in 1912 he introduced acriflavine as trypanocide, it has proved 
to be more valuable as an antiseptic. Phenazopyridine (pyridium) 3 was introduced for the 
same purpose in 1926, and although it is relatively ineffective it has continued to be used 
since it has some analgesic action. 
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Aims and objectives  
Taking in view of the applicability of heterocyclic compounds, we have undertaken the 
preparation of heterocyclic compounds bearing pyridines, pyrimidines and Tetrahydrothieno 
[2, 3 -c] pyridines nucleus. The placements of a wide variety of substituents on these nuclei 
have been designed in order to evaluate the synthesized products for their pharmacological 
profile against selected strains of bacteria and fungi. 
During the course of work, looking to the application of heterocyclic compounds, 
several entities have been designed, generated and characterized using spectral studies. The 
details are as under.  
1.  To generate several derivatives of spiro pyridines and their benzamides derivatives 
Such as chloro-amine coupling, Suzuki coupling, ether coupling and chloro-thio 
coupling etc. 
2.  To generate several derivatives of spiro pyrimidine and their piperazine derivatives 
such as benzoylpiperazine and benzenesulfonyl piperazine etc. 
3.  To generate several derivatives of Tetrahydrothieno [2, 3-c] pyridines such as Schiff 
base & its cyclized product and urea derivatives. 
4.  To check purity of all synthesized compounds using thin layer chromatography.  
5.  To characterize these synthesized products for structural elucidation using various 
Spectroscopic techniques like IR, 1H NMR, mass spectral studies and C, H, N 
analysis. 
6.   To evaluate these new synthesized products for drug potential against different 
strains of bacteria and fungi. Antimicrobial screening to the level of minimum 
inhibitory concentration of each compound of the series, using Agar Dilution Method. 
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Accordingly the work presented in the thesis is discussed as under 
PART-I : STUDIES ON PYRIDINES. 
PART-II : STUDIES ON PYRIMIDINES. 
PART-III : STUDIES ON TETRAHYDROTHIENO [2, 3-c] PYRIDINES. 
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Part-I (Pyridylspiro derivatives) 
INTRODUCTION 
Pyridine is a heterocyclic organic compound with the chemical formula C5H5N. It 
is structurally related to benzene, with one CH group replaced by a nitrogen atom. It is 
used as a precursor to agrochemicals and pharmaceuticals and is also an important reagent. 
The pyridine ring occurs in many important compounds, including the vitamins 
nicotinamide and pyridoxal. 
Preparation and occurrence 
Pyridine was originally industrially produced by extraction from coal tar. It is 
currently synthesized from formaldehyde, ammonia, and acetaldehyde: 
CH2O + NH3 + 2 CH3CHO → C5H5N + 3 H2O + 2 H2  
This process (Chichibabin pyridine synthesis) involves the intermediacy of 
acrolein. An estimated 26,000 tons were produced worldwide in 1989. Condensations of 
ammonia sources and related unsaturated carbon sources affords alkyl- and aryl-
substituted pyridines, e.g. monomethyl compounds (picolines), dimethyl compounds 
(lutidines), and trimethyl derivatives (collidines) [1]. Pyridine occurs in numerous plants, 
although this was mostly recorded just by smell. Goris and Larsonneau [2]  show definite 
evidence of its presence in belladonna leaves, while Kuhn and Schäfer [3] [4] of its presence 
in the roots of the same plant. 
For specialized applications, the synthesis of the pyridine skeleton is well 
developed.[5] The Hantzsch pyridine synthesis, for example, is a multicomponent reaction 
involving formaldehyde, a keto-ester and a nitrogen donor. The Kröhnke pyridine 
synthesis involves the condensation of 1, 5-diketones with ammonium acetate in acetic 
acid followed by oxidation. The Ciamician-Dennstedt Rearrangement entails the ring-
expansion of pyrrole with dichlorocarbene to 3-chloropyridine.[6] In the Gattermann-Skita 
synthesis, [7] a malonate ester salt reacts with dichloromethylamine. [8] 
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Synthetic Aspects 
Yang et al [9] Systematic SAR studies of the different regioisomers and 
homologues of the spiro (indane-1, 4′-piperidine) moiety in the growth hormone 
secretagogue L-162,752. Among them, spiro (3H-1-benzopyran-2, 3′-piperidine) was 
found to afford secretagogue with low nanomolar in vitro activity. This paper describes 
various methods for the preparation of spiro derivatives having Pyridine moiety which 
can be explained as below. 
NH
O
OH
NH
O
NH
O
O
NH
O
N
OO
O
NH
O
O
OH NH
O
NH
O
N
O
O
Pd(OH)2
Ethanol
1. NaBH4
2. Pd(OH)2/C/H2
ethanol
1. aq. HCl, ethanol
heating
2. NaBH4
3. H2/ Pd(OH)2/C
ethanol
1. pyrrolidine
2. aq HCl, ethanol
heating
3. NaBH4
H2/ Pd(OH)2/C
ethanol
1. pyrrolidine
2. aq HCl, ethanol
heating
3. NaBH4
H2/ Pd(OH)2/C
ethanol  
 
Recently Uto et al [10] describes Modification of the benzoylpiperidine part of (A) 
led to a cluster of novel and potent spiropiperidine-based stearoyl-CoA desaturase (SCD)-
1 inhibitors. After comprehensive optimization, a potent and orally bioavailable 
spiropiperidine-based SCD-1 inhibitor (B) was identified. 
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Cyclization
 
 
WO2007/136605 [11] relates to a novel class of aryl-fused spirocyclic compounds. 
These compounds can inhibit histone deacetylase and are suitable for use in selectively 
inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic 
cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present 
invention are useful in treating a patient having a tumor characterized by proliferation of 
neoplastic cells. The compounds of the invention may also be useful in the prevention and 
treatment of TRX- mediated diseases, such as autoimmune, allergic and inflammatory 
diseases, and in the prevention and/or treatment of diseases of the central nervous system 
(CNS), such as neurodegenerative diseases. The present invention further provides 
pharmaceutical compositions comprising the compounds of the instant invention and safe 
dosing regimens of these pharmaceutical compositions, which are easy to follow, and 
which result in a therapeutically effective amount of these compounds invivo. 
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WO94/13696 [12] disclosed certain novel compounds identified as spiro piperidin 
and homologs which promote the release of growth hormone in humans and animals. This 
property can be utilized to promote the growth of food animals to render the production 
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of edible meat products more efficient, and in humans, to treat physiological or medical 
conditions characterized by a deficiency in growth hormone secretion, such as short 
stature in growth hormone deficient children, and to treat medical conditions which are 
improved by the anabolic effects of growth hormone. Growth hormone releasing 
compositions containing such spiro compounds as the active ingredient thereof are also 
disclosed Growth hormone, which is secreted from the pituitary, stimulates growth of all 
tissues of the body that are capable of growing. In addition, growth hormone is known to 
have the following basic effects on the metabolic processes of the body: 
1. Increased rate of protein synthesis in all cells of the body. 
2. Decreased rate of carbohydrate utilization in cells of the body. 
3. Increased mobilization of free fatty acids and use of fatty acids for energy. 
 
A deficiency in growth hormone secretion can result in various medical disorders, 
such as dwarfism. 
This application covers certain spiro compounds which have the ability to 
stimulate the release of natural or endogenous growth hormone. The compounds thus 
have the ability to be used to treat conditions which require the stimulation of growth 
hormone production or secretion such as in humans with a deficiency of natural growth 
hormone or in animals used for food production where the stimulation of growth hormone 
will result in a larger, more productive animal. 
Preferred compounds are of following formula: 
N
O
O O
O
NH2
 
It describes following synthetic methodology for the synthesis of spiro chromane 
derivatives. 
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As illustrated in Scheme, the spiro [2H-l-benzopyran-2, 4’-piperidine] analog 
can be prepared from a substituted or unsubstituted 2-hydroxyacetophenone and a 
properly protected 4- piperidone as described by Kabbe, H. J. Synthesis 1978. 886-
887. The 2- hydroxyl acetophenones, in turn, are either commercially available or can 
be prepared by routes in the literature known to those skilled in the art. Such methods 
are described by Chang, C. T. et al, in J. Am. Chem. Soc, 1961. 3414-3417. and by 
Elliott, J. M. et al, in J. Med. Chem. 1992. 35, 3973-3976. Removal of the protecting 
group as described in: Protective Groups in Organic Synthesis, Greene, T. W., Wuts, 
P. G., John Wiley & sons, New York, 1991, and Olofson, R.A. et al, J. Org. Chem. 
1984. 49, 2081-2082, provide the amine. 
 
The reduction of substituted spiro-piperidinyl chromanone oximes with DIBAH 
reagents [13] has been known to afford the corresponding substituted 4, 5-dihydro-3H-
spiro [1, 5]-benzoxazepine-2, 4′-piperidine. The position and electronic effects of the 
substituents on the aryl moiety control the   observed rearrangement.  Spiro-
benzoxazepine analogue represents a key intermediate for the creation of a library of 
diverse potential bioactive drugs. With three functional  groups  that  could  be  
selectively  and  orthogonally  protected,  many  different substituents  can  be  
introduced.  The obtained analogues were assayed as the possible aspartyl protease 
inhibitors HIV protease (HIV-1) and β-secretase (BACE-1). 
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Structural modification of the isocoumarin moiety of 1'-benzylspiro- 
[isocoumarin-piperidines] [14], which inhibit the compound 48/80-induced release of 
histamine from isolated rat peritoneal mast cells, was undertaken to clarify the structure-
activity relationship. Chromanone (3), chroman (4), 1, 3-benzoxazine (5), 1, 3-
benzothiazine (6), and 4-quinazolinone (7) analogs were active, although there were 
differences in potency. Substituent effects on the benzene moiety of 3 were examined.   
 
O
N
O
R
NH
S
N
O
Inhibition of hisamine release from isolated rat peritoneal mast 
cell by Spiro [chromanone-2,4-piperidines]
3 10
R= H/OH/OMe/Cl/Br/Ph  
 All the above compounds (in hydrochloride form) were showing remarkable effects on “% 
inhibition of histamine release” at various concentrations. 
 
Raab et al [15] disclosed synthesis of following compounds. 
N
O
OH
NH2
N
N
O
O
NH2
N
Si
+ N
N
Si
 
N-benzyl substituted spiro derivatives [16] have been synthesized by various methods as 
depicted below: 
Willand et al describe the three-step synthesis of a novel 4, 5-dihydro-3H-spiro [1, 
5- benzoxazepine-2, 4′-piperidine] scaffold from ortho-hydroxyacetophenone and N- 
benzylpiperidone. The structure of one disubstituted derivative, studied by NOESY NMR 
in an aqueous medium and X-ray diffraction, demonstrates that this scaffold presents side 
chains in a well-defined orientation. The Boc protected derivative represents a key 
intermediate for the combinatorial synthesis of drug-like molecules. 
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N
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O
N
NH
OO
O
3 steps
scaffold for multisite functionalization  
 
 
L-Proline is utilized as an efficient organocatalyst for the synthesis of substituted 
flavanones and chalcones in good yields [17]. The efficiency of the catalyst was proved 
with a variety of substrates ranging from electron-deficient to electron-rich aryl 
aldehydes and 2-hydroxyacetophenones. 
R'
R
O
OH
R''
H
O
O
R'
R R''
O
+
L-proline
DMF, 80 °C
18 hrs
 
 
Masatoshi et al. have reported reduction of oxo group as depicted below 
 
N
O
O
N
O
1) Yield=87 %, NaBH4
, 10 % NaOH/ethanol/2h/Heating
2) Yield=90 %, 20 % H2SO4/1h/Heating
3)Yield= 96 %, H2/5 % Pd-C/ethanol  
 
Elliott et al [18] reported compound having heterocyclic substitution on N-atom. 
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Nerenberg et al [19] reported 4-oxospiro [benzopyran-2,4′-piperidine] ring system 
contained within potent class III antiarrhythmic agents.  
 
O
OH
O
O
N
O
N
N
H
O O
N
N
H
O
OH
N
O
O O
+ +
 
 
 
 
WO2010/002010 [20] relates to a compound of a general formula (I): 
The compound of the invention is useful as therapeutically agents for various 
ACC-related diseases. It describes various methods for the synthesis of novel compounds. 
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WO2009/126584 [21] reports gem-disubstituted or spirocyclic pyridine, pyrimidine and 
triazine derivatives that are useful in the treatment of CDK4-mediated disorders, such as 
cancer.  
N
N
O
N
O
NH2
N
N
O
N
O
NH
N
N
 
 
The compounds exemplified herein have been assayed.  
EP2110377 [22] provides Spirocyclic derivatives as histone deacetylase inhibitors. 
The compound of the invention has following general structural formula 
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WO2009/97309 [23] provides compounds of Formula (I): their use as H3 
antagonists/inverse agonists.  The  location  and  function  of  histaminergic  neurons  in  the  
CNS  suggests  that compounds interacting with the  H 3 receptor may have utility in a 
number of therapeutic applications including narcolepsy or sleep/wake disorders, feeding 
behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood 
attention alteration, attention deficit.  Hyperactivity disorder (ADHD), Alzheimer’s 
disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, 
psychiatric disorders and epilepsy.  
The compounds of the invention have cyclobutyl or cyclopentyl ring on the nitrogen 
atom of spiro piperidine derivatives. The structures can be shown as below. 
O
N
N
N
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Synthetic methods can be depicted as below. 
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WO2008/88692 [24] provides compounds useful as therapeutical agents for 
various ACC-related diseases. ACC  inhibitors are expected to be useful for the 
treatment and/or prevention of disorders  such  as  hyperlipemia,   fatty  liver,  
dyslipidemia,  hepatic  dysfunction,  obesity, diabetes,  insulin  resistance,  metabolic  
syndrome,  arteriosclerosis,  hypertension,  cardiac angina, heart failure, cardiac 
infarction, stroke, claudication,  retinopathy,  eyesight failure, renal failure, electrolyte 
metabolism disorder, neuropathy, skin ulcer, bulimia,  pancreatitis, emmeniopathy, 
arthritis, gout, cholecystitis, gastro esophageal reflux, pickwickian syndrome, sleep 
apnea syndrome, neoplasm, infectious diseases, such as parasite infection, bacterial 
infection, viral infection, and fungal infection, and also as herbicides. This application 
provides compounds of following general formula. 
.T
u
v
N
O
Ar1
OR
1
R2 Ar2
 
 
  Above compounds were tested in the assay and found to have a percent inhibition 
of greater than or equal to 50% for ACC-I and a percent inhibition of greater than or 
equal to 50% for ACC-2 in the acetyl Co-A carboxylase (ACC) activity inhibition test. 
  
WO2008/65508 [25] provides compounds of Formula (1) or a pharmaceutically 
acceptable salt of said  compound  use  thereof  in  treating  mammals  suffering  from  
the  condition of being overweight.  
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Specific compounds synthesized in this application are having indazole side 
chain attached on spiro piperidine nitrogen atom. 
 
O
N
R1
R2 R4
O
O
N
N
H
R3
O
N
R1
R2
O
O
N
N
R4
R3
Ra+
R9
O
N
R1
R2
O
O
N
N
R3
R4
O
N
R1
R2
O
O
N
N
H
R3
Cl
R4
Rb+
 
 
Recently the spirochromanone derivatives are reported for various spirochromene 
pharmacological activities e.g. [26-39].  
 
Current work: 
Keeping all the above facts in the mind, the newer spiropiperidylchromons derivatives 
bearing Pyridyl substitution (for getting better therapeutic agents) have been prepared. 
The work is further subdivided into following sections. 
I. Preparation, Characterization and antimicrobial evaluation of 4-(substituted amino)-3-
nitro-N-[6-{4-oxo-3, 4-dihydro-1’H-spiro-(chromene-2, 4’-piperidin)-1’-yl} pyridine-3-
yl]-benzamides. 
II. Preparation, Characterization and antimicrobial evaluation of 4-(substituted phenoxy)-
3-nitro-N-[6-{4-oxo-3,4-dihydro-1’H-Spiro-(chromene-2,4’- piperidin)-1’-yl} pyridine-
3-yl]-benzamides. 
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III. Preparation, Characterisation and Antimicrobial Evaluation Of 4-(Substituted 
Thiophenoxy)-3-Nitro-N-[6-{4-Oxo-3, 4-Dihydro-1’H-Spiro-(Chromene-2, 4’- 
piperidin)-1’-yl} Pyridine-3-yl]-Benzamides.  
IV. Preparation, Characterization and antimicrobial evaluation of 4-(substituted phenyl)-3-
nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro-(chromene-2, 4’-piperidin)-1’-yl} pyridine-
3-yl]-benzamides. 
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SECTION-I 
 
Preparation, Characterization and antimicrobial evaluation of 4-(substituted 
amino)-3-nitro-N-[6-{4-oxo-3,4-dihydro-1’H-spiro-(chromene-2,4’-piperidin)-1’-
yl}pyridine-3-yl]-benzamides. 
Keeping in view of wide spectrum biodynamic activities[1-39] of Pyridine 
and with a view to have potent therapeutic agents, the synthesis of 4-(substituted 
amino)-3-nitro-N-[6-{4-oxo-3,4dihydro-1’H- spiro-(chromene-2,4’- piperidin)-1’-
yl}pyridine-3-yl]-benzamides (1a-k) have been synthesized by the nucleophilic 
substitution of the chloro atom of  4-chloro 3-nitro- N-[6-{4-oxo-3,4 dihydro-1’H- spiro-
(chromene-2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides with different substituted 
amines. 
 
 
 
 
 
 
 
 
 
 
(1a-k) 
R= Substituted amino 
The constitution of the synthesized products (1a-k) have been 
characterized by using elemental analyses, infrared and 1H nuclear magnetic 
resonance spectroscopy and further supported by mass spectrometry. Purity of 
all compounds has been checked by thin layer chromatography. 
All the compounds have been evaluated for their antibacterial activity 
against Gram Positive bacteria like Staphylococcus aureus, Bacillus subtilis and 
Gram Negative bacteria like Escherichia coli, Salmonella peratyphi B and they 
were also evaluated for antifungal activity against Candida albicans and 
Aspergillus niger at different concentrations: i.e. Primary screening at 2000 to 
1000, Secondary screening at 1000 to 250 and tertiary screening at 250 to 3.9 
(µg/ml) for their MIC (Minimum Inhibitory Concentration) values. The 
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antimicrobial activities of the synthesized compounds (1a-k) have been 
compared with standard drugs. Their antimicrobial effect was determined in 
higher dilution using Agar Dilution Method (Approved by NCCLs). 
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REACTION SCHEME 
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REACTION SCHEME 
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EXPERIMENTAL 
Preparation, Characterisation and antimicrobial evaluation of 4-(substituted amino) 
-3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} 
pyridine-3-yl]-benzamides. 
[A] Synthesis of Scaffold-A. 
1. Synthesis of phenyl acetate (Intermediate-3) 
In RBF, Phenol (1.00 mol) and acetic anhydride (excess) were charged. Catalytic 
amount of sulfuric acid was added into the reaction mixture at 0°C. Then reaction mixture 
was allowed to warm at room temperature and stirred for 1-2 hours.  After the completion 
of reaction, reaction mixture was quenched in crushed ice. The product was extracted 
with ethyl acetate. The organic phase was washed with saturated bicarbonate, brine 
solution and dried over sodium sulfate. The organic phase was concentrated under reduce 
pressure at 45°C to get desired product. Yield: 92.00 %, B.P.-218°C. 
2. Synthesis of 2-Hydroxy Acetophenone (Intermediate-4) 
In RBF, Intermediate-3 (1.00 mol) and anhydrous AlCl3 (5.00 mol) were heated to 
1600C for 4-5 hours. Then reaction mixture was cooled to 80°C and quenched in diluted 
hydrochloric acid. The product was extracted with ethyl acetate and the organic layer was 
washed with saturated sodium bicarbonate solution. The organic phase was dried over 
sodium sulphate and concentrated under reduce pressure at 45°C to get crude product 
which was purified by using column chromatography. The product was eluted at 11% 
ethyl acetate in hexane. Yield: 69.00 %, B.P- 93°C. 
3. Synthesis of t-butyl 4-oxo-3, 4-dihydro-1'H- spiro [chromene-2, 4'-piperidine]-1'-
carboxylate. (Intermediate-6) 
In RBF, Intermediate-4 (1.00mol) and Intermediate-5 (1.00 mol) were dissolved 
in ethanol. Then catalytic amount of pyrrolidine was added into the reaction mixture at 
room temperature. The reaction mixture was heated to reflux temperature for 24 hours. 
After the completion of reaction, reaction mixture was concentrated under reduce 
pressure at 45°C. Then obtained residue was quenched in water. The product was 
extracted with ethyl acetate, washed with diluted hydrochloric acid and saturated sodium 
bicarbonate solution. The organic phase was dried over sodium sulphate and concentrated 
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under reduce pressure at 45°C to get crude product. The crude product was purified by 
crystallization in ethanol. Yield: 62.00 %, M.P. 92°C. 
 
4. Synthesis of Spiro [chromene-2, 4’-piperidin]-4(3H)-one. (Intermediate-7) 
 
In RBF, Intermediate-6 (1.00 mol) and triflouro acetic acid was added and stirred 
at room temperature for 2-3 hours. After the completion of reaction, reaction mixture was 
quenched in crushed ice and neutralized with sodium bicarbonate. The Product was 
extracted with ethyl acetate and washed with brine solution. The organic phase was dried 
over sodium sulphate and concentrated under reduce pressure at 45°C to get pure desired 
product. Yield: 90.00%, M.P- 207°C (HCl Salt). 
 
5. Synthesis of 1'-(5-nitropyridin-2-yl) spiro [chromene-2, 4’-piperidin]-4(3H)-one. 
(Intermediate-9). 
In RBF, 2-chloro-5-nitropyridine (Intermediate-8) (1.00 mol), Intermediate-7 
(1.05 mol) and DMF were added at room temperature. Then cesium carbonate (2.50mol) 
was added into the reaction mixture at 0°C and reaction mixture was allowed to warm at 
room temperature and stirred for 4-5 hours at same temperature. After the completion of 
reaction, reaction mixture was quenched in chilled water. The product was filtered 
through Buckner funnel under vacuum and washed with water.  The solid was dried under 
vacuum at 500C. Yield: 60.00%, M.P. - 237°C. Elemental Analysis: Calculated: C 
(63.71%), H (5.05%), N (12.38%), Found: C (62.12%), H (5.02%), N (11.98%). 
 
6. Synthesis of 1'-(5-aminopyridin-2-yl)-4H-spiro [chromene-3,4'-piperidin]-4-one. 
(Intermediate-10) 
In RBF, Intermediate-9 was dissolved in methanol under nitrogen atmosphere at 
room temperature. In reaction mixture stannous chloride was added portion wise at room 
temperature. Reaction mixture was heated to reflux temperature for 5-6 hours. The 
completion of reaction was confirmed by TLC. After the completion of reaction,   
reaction mixture was allowed cool at room temperature and quenched with diluted 
ammonia solution. The reaction mixture was filtered through highflow bed and washed 
with Methanol. Methanol was evaporated and the residue was diluted with ethyl acetate, 
washed with water and brine solution. The organic phase was dried over sodium sulfate 
and concentrated under reduce pressure at 50°C to get desired crude product. The crude 
product was purified by triturating with diethyl ether. Obtained solid was dried at 45°C. 
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Yield: 65.00 %, M.P. - 194°C. Elemental Analysis: Calculated: C (69.88%), H (6.19%), 
N (13.58%), Found: C (69.11%), H (6.01%), N (12.92%). 
 
7. Synthesis of 4-chloro - 3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro-(chromene-2, 
4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides. (Scaffold-A) 
In RBF, Intermediate-10 (1.20 mol) in THF and K2CO3 (2.50 mol) was added at 
room temperature. In reaction mixture, the solution of 4-chloro,3-nitrobenzoylchloride 
(1.1 eq.) in THF was added drop wise at room temperature and stirred for 1 hour at same 
temperature. Then solvent was removed under vacuum at 45°C. The obtained residue was 
quenched in water to get solid. The solid was filtered, washed with water and dried under 
reduced pressure at 45°C to get pure product.  Yield: 82.00 %, M.P.-219-222°C. 
Elemental Analysis: Calculated: C (60.92%), H (4.29%), N (11.37%), Found: C 
(60.53%), H (4.21%), N (11.01%). 
[B] Synthesis of 4-(Morpholine) -3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro-
(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamide. 
In RBF, Scaffold-A (1.00 mol) in THF and TEA (2.50 mol) was added at room 
temperature. In reaction mixture, Morpholine (2.0 mol) was added at room temperature 
and heated at reflux temperature for 5-6 hour. Then solvent was removed under vacuum 
at 45°C. The obtained residue was quenched in water to get product. The solid was 
triturating with ethanol to get pure product, yield: 58%. M.P.- 235°C. Elemental Analysis: 
Calculated: C (64.08%), H (5.38%), N (12.88%), Found: C (63.99%), H (5.46%), N 
(12.81%). 
Similarly, other compounds (1a-k) were synthesized by above mentioned process (B) 
from Scaffold-A using different aliphatic amines. The physical data are recorded in 
Table-1. 
[C] Antimicrobial activity of 4-(substituted amino) -3-nitro-N-[6-{4-oxo-3, 4 
dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides. 
All the compounds have been evaluated for antimicrobial activity, described as 
under. 
The Activities of all the synthesized compounds are recorded in table no. 1(A) and 1(B). 
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Protocol for studying Antimicrobial activity 
Agar Dilution procedure: 
The Agar Dilution Method for determining antimicrobial susceptibility is a well-
established technique [29, 30]. The antimicrobial agent is incorporated into the agar medium 
in each plate containing a different concentration of the agent. 
Preparation of stock solution: 
10 mg of compound was dissolved in 5 ml of DMSO to prepare the main stock of 
compounds to be tested. 1 ml of this main stock was added to 19 ml of Mueller Hinton 
Agar medium to take the final concentration of 1000 µg/ml in the agar medium. The main 
stock solution was further diluted in demineralized water by two fold dilution procedure 
to obtain the desired concentration in the agar medium, i.e.2000 µg/ml, 1000 µg/ml 
(Primary screening), 1000 µg/ml, 500 µg/ml 250 µg/ml (Secondary screening), 250 
µg/ml, 125 µg/ml, 62.5µg/ml 31.2 µg/ml, 15.6 µg/ml, 7.8µg/ml, 3.9 µg/ml, 1.9 µg/ml, 
0.45 µg/ml, 0.22 µg/ml (Tertiary screening). 
 
Reagents and Materials: 
Microorganisms and Media: 
ATCC Bacterial cultures obtained from NCL, Pune were 
1.  Escherichia coli ATCC 25922 
2. Staphylococcus aureus ATCC 25923 
3. Bacillus subtilis ATCC 6633 
4. Candida albicans ATCC 10231 
Clinical isolates from Civil Hospital, Rajkot and Medical College, Jamnagar were 
1. Escherichia coli 
2. Staphylococcus aureus 
3. Salmonella peratyphi B 
4. Candida albicans 
5. Bacillus subtilis 
6. Aspergillus Niger 
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Muller Hinton Agar medium 
Muller Hinton Agar medium was used to carry out antimicrobial analysis of newly 
synthesized compounds. The composition of Muller Hinton Agar medium is as under 
Composition of Muller Hinton Agar      G/liter 
Beef Infusion        300.00 
Casein acid hydrolysate        17.50 
Starch             1.5 
Agar           17.50 
Final pH (at 25°C)      7.3+0.2 
Preparing Agar Dilution plates: 
(1) Appropriate dilution i.e. 1.00 ml quantity of antimicrobial solution are added to 
molten test agars having 19.0 ml quantity that have been allowed to equilibrate in a water 
bath to 45 to 50°C. One part of antimicrobial solution is added to nine parts of liquid agar. 
(2) The agar and antimicrobial solution were mixed thoroughly and the mixtures poured 
into borosil glass petridishes having 9 cm diameter on a level surface to result in an agar 
depth of 3 to 4 mm. 
(3) The plates should be poured as quickly after mixing as possible to prevent cooling and 
partial solidification in the mixing container, avoiding bubbles. 
(4) The agar was allowed to solidify at room temperature and the plates were either used 
immediately or stored in sealed plastic bags at 2 to 8°C for up to five days for reference 
work or longer for routine tests. 
(5) Plates stored at 2-8°C were allowed to equilibrate at room temperature before use, 
assuring that the agar surface was dry before inoculating the plates. If necessary, plates 
were placed in an incubator to hasten drying of the agar surface. 
 
Source of Antimicrobial agents: 
It was stored in air tight container or under desiccation at 40C if in powder form. 
All synthetic organic compounds were analyzed for their antimicrobial activity by Dr. 
Chetanaben Rajyaguru, Asst. professor, Microbiology department, MVM Science and 
Home science college, Rajkot. 
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Control plates: 
(1) Drug-free plates prepared from the medium were used as growth controls. These 
plates were free from Antimicrobial agents as well as solvent. 
(2) Control plates prepared from the base medium with addition of only 1.00 ml solvent 
DMSO (free of antimicrobial agents), were called as solvent control plate. 
Inoculation: 
One loopful of culture from the slant was inoculated into 5 ml Muller Hinton 
broth in a test tube. The tube was incubated at 32°C for 4 to 6 hours till the absorbance at 
625 nm, equals that of 0.5 Mac Farland standard. The absorbance readings were taken 
against a sterile Muller Hinton broth Media blank. The density of the suspension was 
adjusted to 108 colony forming units (CFU) per milliliter by comparing its turbidity to a 
MacFarland 0.5 BaSO4 standard. 
The bacterial cultures were then transferred at 2-8°C and maintained at the same 
temperature till further use. Appropriate dilution of the bacterial cultures were made 
based on the viable count of the bacterial cultures previously done to establish the 
relationship between absorbance at 625 nm and viable count before inoculating the plates 
with the antimicrobial test agents of this 2 µg/ml diluted culture was used to spot 
inoculate the plates with antimicrobial agents using micropipette. 
 
Preparation of 0.5 Mac Farland standards: 
It was used as a reference for turbidity measurement for bacterial cultures before 
they were used as inoculums for spot inoculate the Mueller Hinton Agar media containing 
antimicrobial agents. 
Briefly, 0.5 ml of 1.175% w/v BaCl2 solution was added to 99.5 ml of 1% v/v 
H2SO4 solution with constant stirring, the absorbance of the solution was measured 625 
nm against demineralized water blank by UV spectrophotometer. The absorbance was in 
the range of 0.08 to 0.1 optical densities. 
Incubation:  
All plates were kept after inoculation at 37°C for 24 hours in an ambient air incubator. 
(II) Antifungal activity 
Standard drug ciprofloxacin and fluconazole were used to investigate the MICs of 
standard bacterial and fungal ATCC cultures. 
These MICs were used for the comparison of MICs of newly synthesized organic 
compounds. 
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Microbial culture      Ciprofloxacin 
1. Escherichia coli ATCC 25922     0.4 µg/ml 
2. Staphylococcus aureus ATCC 25923    1.9µg/ml 
3. Bacillus Subtilis ATCC 6633     7.8µg/ml 
4. Salmonella peratyphi B              1.4µg/ml  
Fungal culture      Fluconazole 
1. Candida albicans       0.4 µg/ml 
2. Aspergillus Niger                                                                 0.7 µg/ml 
Antifungal Activity Determination: 
For fungal culture the fungal media Yeast Nitrogen Base Agar plate (YNBG) 
(Difco make) 6.7gm and Glucose 10 gm dissolved in 100 ml distilled water and filter 
sterilized was used. The inoculums were prepared from 3-4 days old sabourauds Dextrose 
agar slants. The growth was uniformly mixed with distilled water. The size of Inoculum 
prepared for inoculating YNBG agar plates was 102 -103 cfu/ml, adjusted with 
MacFarland solution. After inoculation of properly diluted fungal solution, the plates 
were incubated at 37°C for 48 hours. 
Quality Control: 
(1) Growth control was performed to check viability of the organisms. 
(2) Purity control by sample inocula streaked on a suitable agar plate. 
(3) Inoculum control by plate counts was performed on representative 
     Inoculum periodically. 
(4) End point interpretation control was independently read for all dilution 
                 Plates. 
Rigorous quality control was maintained through the experimentation by checking 
large numbers of variables that may affect the results. Physical and chemical 
characteristics of Mueller Hinton agar media were monitored, such as pH and depth of 
agar. The final control was provided by a series of reference strains including Escherichia 
coli ATCC 25922, Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC 6633, 
Candida albicans ATCC 10231. The reference strains were stored at temperature below -
20°C. 
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Determination of type of Antimicrobial Activity: 
Organic compounds may be bacteriostatic or bactericidal for microbial cultures. 
To check this, sub culturing was carried out from the Mueller Hinton Agar plates showing 
no visible growth of bacteria on to Nutrient Agar plates. After streaking Nutrient Agar 
plates were well incubated for 24 hours in incubator at 37°C temp. Then after observation 
was made to see the colonies formed. If colonies were found the dilution was considered 
as bacteriostatic and if no colonies observed, it was considered as bactericidal. 
Bactericidal dilution of the organic compounds was considered as exact MIC (Minimum 
inhibitory concentration) for a particular organic compound. 
 
Interpretation of Results: 
1. In case of positive control plate due to complete absence of antimicrobial agent and        
its solvent bacterial/ fungal cultures gave luxuriant growth. 
2. in the solvent control plate little inhibition of growth of microbes due to presence of 
    organic solvent DMSO.   
3. The microbial cultures, if shown 1-5 colonies per spot inoculated instead of confluent 
growth as in the control plate, it was considered to be inhibited by test antimicrobial 
compounds. 
4. The microorganisms that were sensitive to the concentration of antimicrobial agent in 
Mueller Hinton agar plate did not produce a circle of growth at the Inoculum site. 
5. The microbes that were resistant to it appeared as circular colonies. The agar plates 
were marked with a grid so that each microorganism could be identified by a number. 
 
 
 
 
 
 
 
 
 
 
Pyridyl Spiro Derivatives… 
Part-1 (Section-I)… 
 
37 
TABLE NO-1: Physical constants of 4-(substituted amino) -3-nitro-N-[6-{4-oxo-3, 4-
dihydro-1’H-spiro-(chromene-2, 4’-piperidin)-1’-yl} pyridine-3-yl]-benzamides (1a-
k). 
Sr. 
No. 
Substitution 
R M.F./ M.W. 
M.P. 
°C 
Yield
% 
% Composition 
Calcd./Found 
C H N 
1a 
N
O  
C29H29N5O6 
543 
 
235 
 
58 
64.08 
63.99 
5.38 
5.46 
12.88
12.81
1b NNCH3  
C30H32N6O5 
556 
136 45 
64.73 
64.52 
5.79 
5.41 
15.10
14.26
1c N  
C29H29N5O5 
527 
181 62 
66.02 
65.80 
5.54 
5.32 
13.27
13.11
1d N
 
C30H31N5O5 
541 
192 63 
66.53 
66.38 
5.77 
5.60 
12.93
12.71
1e N
N
H
CH3O
 
C31H32N6O6 
584 
160 50 
63.69 
63.54 
5.52 
5.30 
14.38
14.10
1f N
CH3
CH3
 
C27H27N5O5 
501 
138 65 
64.66 
64.26 
5.43 
5.14 
13.96
13.62
1g N N
OH
 
C31H34N6O6 
586 
155 40 
63.47 
63.15 
5.84 
5.45 
14.33
14.13
1h N
CH3
 
C30H31N5O5 
541 
167 61 
66.53 
66.39 
5.77 
5.53 
12.93
12.71
1i NNOH
 
C35H34N6O6 
634 
192 48 
66.23 
65.51 
5.40 
5.31 
13.24
13.09
1j N
OH
 
C30H31N5O6 
557 
194 75 
64.62 
64.36 
5.60 
5.26 
12.56
12.30
1k N
O
CH3
CH3  
C31H33N5O6 
571 
209 78 
65.14 
65.01 
5.82 
5.58 
12.25
12.10
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IR Spectral Study of 4-morpholine -3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro-
(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides (1a). 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:  4000-400 
cm-1 (KBr disc.) 
Type Vibration Mode Frequency in cm-1 Ref. No. 
Observed Reported  
Alkane C-H asym. str. 
C-H sym. str. 
C-H asym. def. 
C-H sym. Def. 
2949 
2840 
1462 
1359 
2975-2850 
2900-2800 
1460-1400 
1385-1300 
42 
42 
42 
42 
Aromatic C-H str. 
C=C ring skeleton 
 
p-disubstituted benzene 
3066 
1531 
1492 
840 
3080-3010 
1600-1450 
1600-1450 
850-750 
42 
44 
44 
44 
Pyridine 
moiety 
-C=N str. 
C-N str. 
C-NO2 asym. Str. 
1684 
1304 
1550 
1690-1570 
1310-1250 
1570-1500 
43 
43 
43 
Chromanone 
moiety 
C-O-C asym. Str. 
C-O-C sym. Str. 
Cyclic C=O str. 
1240 
1030 
1684 
1250-1200 
1050-1010 
1740-1630 
42 
42 
42 
Amide Ketone -C=O str. 
N-H str. 
1647 
3371 
1740-1650 
3500-3310 
42 
43 
 
40060080010001200140016001800200024002800320036004000
1/cm
-30
-15
0
15
30
45
60
75
90
105
%T
33
71
.6
8
30
66
.9
2
29
49
.2
6
16
83
.9
1
16
47
.2
6
16
18
.3
3
15
31
.5
3
14
92
.9
5
14
62
.0
9
13
59
.8
6
13
03
.9
2
12
40
.2
7
12
22
.9
1
11
90
.1
2
11
22
.6
1
10
30
.0
2
92
0.
08
84
6.
78
76
5.
77
70
5.
97
SDU-1..
O
N
O
N
NH
O
NO2
N
O
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1H-NMR Spectral Study of 4-morpholine -3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- 
spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides (1a). 
N
O
NH
O
N
O
NO 2
O
ab
c
d
d
e
f
f
g
h
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Instrument: BRUKER 400 MHz (Advance - II), Internal reference: TMS, 
Solvent: DMSO- d6. 
 
 
  
Serial 
No. 
Signal Position 
(δ ppm) 
Relative No. 
of Protons 
Multiplicity Inference 
1 1.74 2H triplet -(CH2) a 
2 1.95 2H triplet -(CH2) b 
3 2.872 2H Singlet -(CH2) c 
4 3.050 4H Triplet -(CH2)2 d 
5 3.258 2H Triplet -(CH2) e 
6 3.71 4H Triplet -(CH2) f 
7 3.959 2H Triplet -(CH2) g 
8 6.900-8.456 10H complex Ar-H 
9 10.19 1H Singlet -(NH) h 
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1H NMR spectra of 4-Pyrrolidine -3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro-
(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides. 
N
O
N
NH
O
NO 2
N
O
ab
b
b
c
d
d
ef
g
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Instrument: BRUKER 400 MHz (Advance - II), Internal reference: TMS, 
Solvent: DMSO- d6. 
 
  
Serial 
No. 
Signal Position 
(δ ppm) 
Relative No. 
of Protons 
Multiplicity Inference 
1 1.74 2H Triplet -(CH2) a 
2 1.96 6H Multiplate -(CH2)3 b 
3 2.87 2H Singlet -(CH2) c 
4 3.22 4H Triplet -(CH2)2 d 
5 3.25 2H Multiplate -(CH2) e 
6 3.95 2H Multiplate -(CH2) f 
7 6.895-8.430 10H complex Ar-H 
8 10.06 1H Singlet -(NH) g 
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Mass Spectral Study of 4-morpholine -3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro-
(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides (1a). 
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Possible Mass Fragmentation pattern: 
N
O
NO2
N
H
O
O
N
H
O
O
m/z= 170
m/z= 212
m/z= 217
m/z= 280
m/z= 410
m/z= 352
m/z= 493
m/z= 363
m/z= 459
m/z= 148
+
.°
+
°
+ + +
+
+
+
+
+
°
° °
°
°
°
m/z= 543 (M+)
N
O
N
NH
O
NO2
O
N
O
O
O
N
O
N
N
O
N
NH
O
NO2
O
N
O
N
O
N
NH
O
O
N
O
N
NH
O
O
OH
N
N
NH
O
NO2
N
O
N
O
N
NH
O
NO2
O
.°
O
+
°
m/z= 105 
base peak
°
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CONCLUSION 
ANTIMICROBIAL ACTIVITY 
 
The newly synthesized organic compounds were screened through three different 
types of screening i.e. (1) Primary Screening using 2000 µg/ml conc. (2) Secondary 
Screening 1000 µg/ml to 250 µg/ml conc. (3) Tertiary Screening start from 125 µg/ml to 
3.9 µg/ml. The compounds which were active against the microbes in primary screening 
were taken for the secondary screening. The compounds which gave inhibition of 
microbes in secondary screening were further analyzed for tertiary screening. 
From the results of experiments using newly synthesized organic compounds’ it is 
clear that all the compounds were moderately active at lower dilution i.e. high 
concentration like 2000 µg/ml and 1000 µg/ml conc. of compounds. In the series 1a-k 
almost six compounds 1b, 1d, 1e, 1f, 1h and 1j were found active at 500 µg/ml conc. 
against staphylococcus aureus. Bacillus Subtilis was inhibited at 500 µg/ml conc. by eight 
compounds 1b, 1c, 1d, 1e, 1f, 1g, 1h, and 1k. Five compounds 1b, 1d, 1e, 1f and 1h were 
active against both cultures B.Subtilis and S.aureus. At the conc. 250 µg/ml S. aureus was 
inhibited by two compounds Ib and Id. B.Subtilis was not killed by any compounds (1a-
k). So, it is obvious from the data obtained that compounds 1b and 1d were highly active 
among all the compounds of series 1a-k. 
For Gram Negative bacteria in the series Ia-k almost six compounds 1b, 1d, 1e, 
1h, 1j and 1k were found active at 500 µg/ml conc. against Escherichia Coli. S.Paratyphi 
B. was inhibited at 500 µg/ml conc. by eight compounds i.e.  1b, 1d, 1e, 1f, 1g, 1h, 1j and 
1k. So, six compounds were active against both cultures E.Coli and S.Paratyphi B. i.e. 1b, 
1d, 1e, 1h, 1j and 1k. At the conc. 250 µg/ml E.Coli was not killed by any compound (1a-
k). S.Paratyphi B. was also inhibited by one compound 1b. So, it is obvious from the data 
obtained that compound 1b was highly active among all the compounds of series 1a-k. 
For fungi in the series Ia-k almost seven compounds 1b, 1c, 1d, 1e, 1h, 11 and 1j were 
found active at 500 µg/ml conc. against A.niger. C. albicans was inhibited at 500 µg/ml 
conc. by six compounds i.e. 1b, 1d, 1g, 1h, 11 and 1j. At the conc. of 250 µg/ml 
C.albicans was killed by one compound 1b. A. Niger was killed by two compounds i.e. 1b 
and 1h. So, it is obvious from the data obtained that compound 1b was highly active 
among all the compounds of series 1a-k. 
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SECTION-II 
 
Preparation, Characterization and antimicrobial evaluation of 4-(substituted 
phenoxy)-3-nitro-N-[6-{4-oxo-3,4-dihydro-1’H-Spiro-(chromene-2,4’- piperidin)-
1’-yl} pyridine-3-yl]-benzamides. 
Keeping in view of wide spectrum biodynamic activities[1-39]  of Pyridine 
and with a view to have potent therapeutic agents, the synthesis of 4-(substituted 
phenoxy)-3-nitro-N-[6-{4-oxo-3,4-dihydro-1’H-Spiro-(chromene-2,4’- piperidin)-
1’-yl}pyridine-3-yl]-benzamides (2a-k) have been synthesized by the 
nucleophilic substitution of the chloro atom of  4-chloro 3-nitro- N-[6-{4-oxo-3,4 
dihydro-1’H- spiro-(chromene-2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides with 
different substituted phenols. 
 
 
 
 
 
 
 
 
 
(2a-k) 
                                              R= Substituted phenoxy 
The constitution of the synthesized products (2a-k) have been characterized by 
using elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy 
and further supported by mass spectrometry. Purity of all compounds has been 
checked by thin layer chromatography. 
All the compounds have been evaluated for their antibacterial activity against 
Gram Positive bacteria like Staphylococcus aureus, Bacillus subtilis and Gram 
Negative bacteria like Escherichia coli, Salmonella peratyphi B and they were also 
evaluated for antifungal activity against Candida albicans and Aspergillus niger at 
different concentrations: i.e. Primary screening at 2000 to 1000, Secondary screening 
at 1000 to 250 and tertiary screening at 250 to 3.9 (µg/ml) for their MIC (Minimum 
N
O
O
N
NH
O
R
N
+
O
-
O
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Inhibitory Concentration) values. The antimicrobial activities of the synthesized 
compounds (2a-k) have been compared with standard drugs. Their antimicrobial 
effect was determined in higher dilution using Agar Dilution Method (Approved by 
NCCLs). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pyridyl Spiro Derivatives… 
Part-1 (Section-II)… 
 
50
REACTION SCHEME 
 
 
N
N
O
O
NH
O
NO2
Cl
N
N
O
O
NH
O
NO2
R
(Scaffold- A)
substituted phenols
 DMF, K2CO3
R =  substituted phenoxy
Reflux
(2a-k)
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EXPERIMENTAL 
Preparation, Characterization and antimicrobial evaluation of 4-(substituted 
Phenoxy)-3-nitro-N-[6-{4-oxo-3,4-dihydro-1’H-spiro-(chromene-2, 4’- piperidin)-
1’-yl} pyridine-3-yl]-benzamides. 
[A] Synthesis of Scaffold-A. 
For Preparation, see Part-I, Section-I, Page No. (29 to 31) 
[B] Synthesis of 4-(2-fluoro Phenoxy)-3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro 
(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides. 
In RBF, Scaffold-A (1.00 mol) in DMF and K2CO3 (2.50 mol) was added at 
room temperature. In reaction mixture 2-fluorophenol was added at room temperature 
and heated at reflux temperature for 5-6 hour. Then reaction mixture was cooled to 
room temperature and quenched with water to get solid. The solid was filtered under 
vacuum and washed with water. The solid was triturating with ethanol to get pure 
product. Yield: 65% M.P.-155°C. Elemental Analysis: Calculated: C (65.49%), H 
(4.43%), N (9.85%), Found: C (65.43%), H (4.41%), N (9.79%). 
Similarly, other compounds (2a-k) were synthesized by above mentioned 
process [B] from Scaffold-A. The physical data are recorded in Table-2. 
 
[C] Antimicrobial activity of 4-(substituted Phenoxy) -3-nitro-N-[6-{4-oxo-3, 4 
dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides. 
Antimicrobial activity testing was carried out as described in Part-I, Section-I, 
Page No. (32 to 36) The MIC values of test solution are recorded in Table NO-2a and 
2b. 
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TABLE NO-2: Physical constants of 4-(substituted Phenoxy) -3-nitro-N-[6-{4-
oxo-3, 4 dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-
benzamides (2a-k). 
Sr. 
No. 
Substitution 
R 
Molecular 
Formula/ 
Molecular 
weight 
M.P. 
o C 
Yield 
% 
% Composition
Calcd./Found 
C H N 
2a 
O
F
 
C31H25FN4O6 
546 
155  65 
65.49 
65.43 
4.43 
4.41 
9.85 
9.79 
   2b 
Cl
O
 
C31H25CIN4O6 
585 
158  60 
63.65 
63.52 
4.31 
4.20 
9.58 
9.41 
2c 
O
O
CH3
 
C32H28N4O7 
580 
182  70 
66.20 
66.03 
4.86 
4.71 
9.65 
9.41 
2d 
OCH3
CH3
N+
O-
O  
C33H29N5O8 
623 
135  72 
63.56 
63.12 
4.69 
4.41 
11.23 
11.11 
2e 
O
N  
C32H25N5O6 
575 
118  52 
66.78 
66.53 
4.38 
4.23 
12.17 
12.10 
2f 
O
N+
O-
O  
C31H25N5O8 
595 
122  72 
62.52 
62.32 
4.23 
4.08 
11.76 
11.64 
2g 
OO
O
CH3
CH3  
C33H30N4O8 
610 
143  70 
64.91 
64.52 
4.95 
4.63 
9.18 
8.90 
2h 
O
Cl
Cl  
C31H24Cl2N4O6 
619 
159  45 
60.11 
59.84 
3.91 
3.79 
9.04 
8.82 
2i 
OCl
 
C31H25ClN4O6 
585 
155  58 
63.65 
63.49 
4.31 
4.17 
9.58 
9.41 
2j 
O
F  
C31H25FN4O6 
546 
142  62 
65.49 
65.33 
4.43 
4.22 
9.85 
9.69 
2k 
O
Br  
C31H25BrN4O6 
629 
163  65 
59.15 
59.12 
4.00 
3.61 
8.90 
8.59 
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IR Spectral Study of 4-(4’-Methoxy Phenoxy) -3-nitro-N-[6-{4-oxo-3, 4 dihydro-
1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides (2c). 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:  4000-
400 cm-1 (KBr disc.) 
Type Vibration Mode Frequency in cm-1 Ref. No. 
Observed Reported  
Alkane  C-H asym. str.    
C-H sym. str. 
C-H asym. def. 
C-H sym. Def.  
2950
2830
1450
1355
2975-2850 
2900-2800 
1460-1400 
1385-1300 
42 
     42 
     42 
     42 
Aromatic C-H str. 
C=C ring skeleton 
 
p-disubstituted benzene 
3070
1530
1490
830
3080-3010 
1600-1450 
1600-1450 
850-750 
42 
     44 
     44 
     44 
Pyridine 
moiety 
-C=N str.                      
C-N str. 
C-NO2 asym. Str. 
1685
1305
1550 
1690-1570 
1310-1250 
1570-1500 
     43 
     43 
     43 
Chromanone 
moiety 
C-O-C asym. Str. 
C-O-C sym. Str. 
Cyclic C=O str. 
1240
1030
1685
1250-1200 
1050-1010 
1740-1630 
     42 
     42 
     42 
Amide Ketone -C=O str. 
N-H str. 
1650
3370
1740-1650 
3500-3310 
     42 
    43 
N
O
N
NH
O
NO2
O
O
O
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 1H-NMR Spectral Study of 4-(2-fluoro phenoxy) -3-nitro-N-[6-{4-oxo-3, 4 
dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-
benzamides (2a). 
N
O
N
NH
O
NO 2
O
F
O
ab
c
de
f
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Instrument: BRUKER 400 MHz (Advance - 2), Internal reference: TMS, 
Solvent: DMSO-d6. 
 
  
Serial 
No. 
Signal 
Position(δppm)  
 
Relative 
No. of 
Protons 
Multiplicity Inference 
 
1 1.74 2H Triplet -(CH2) a 
2 1.94 2H Triplet -(CH2) b, 
3 2.874 2H Singlet -(CH2) c 
4 3.27 2H Triplet -(CH2) d 
5 3.96 2H Triplet -(CH2) e 
6 6.914-8.689 14H Complex Ar-H 
17 10.36 1H Singlet -(NH) q 
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Mass Spectral Study of 4-(4’-Methoxy-1-phenoxy) -3-nitro-N-[6-{4-oxo-3, 4 
dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides 
(2c). 
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Possible Mass Fragmentation pattern: 
N
O
NO2
N
H
O
O
N
H
O
O
m/z= 170 base peak
m/z= 212
m/z= 217
m/z= 564
m/z= 490
m/z= 288
m/z= 499
m/z= 182
m/z= 474
m/z= 139+
.
°
+
°
+
+ +
+
+
+
+
+
°
° °
°
°
°
°
°
m/z= 580 (M+)
N
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CONCLUSION 
ANTIMICROBIAL ACTIVITY 
 
 The newly synthesized organic compounds were screened through three 
different types of screening i.e. (1) Primary Screening using 2000 µg/ml conc. (2) 
Secondary Screening 1000 µg/ml to 250 µg/ml conc.(3) Tertiary Screening start from 
125 µg/ml to 31.25 µg/ml. The compounds which were active against the microbes in 
primary screening were taken for the secondary screening. The compounds which 
gave inhibition of microbes in secondary screening were further analyzed in tertiary 
screening. 
 
 From the results of experiments using newly synthesized organic compounds 
it is clear that all the compounds were moderately active at lower dilution i.e. high 
concentration like 2000 µg/ml and 1000 µg/ml conc. of compounds. In the series 2a-k 
almost four compounds 2b, 2g, 2h, and 2k were found active at 500 µg/ml conc. 
against staphylococcus aureus. Bacillus Subtilis was inhibited at 500 µg/ml conc. by 
four compounds 2d, 2g, 2h, and 2k. Three compounds 2g, 2h, and 2k was active 
against both cultures B.Subtilis and S.aureus. At the conc. 250 µg/ml S. aureus was 
not killed by any compounds (2a-k).  B.Subtilis was inhibited by two compounds 2h 
and 2k. So, it is obvious from the data obtained that compounds 2h and 2k was highly 
active among all the compounds of series 2a-k. 
 
 For Gram Negative bacteria in the series 2a-k almost nine compounds 2a, 2b, 
2c, 2d, 2e, 2f, 2g, 2h and 2k were found active at 500 µg/ml conc. against Escherichia 
Coli. S.Paratyphi B. was inhibited at 500 µg/ml conc. by nine compounds i.e. 2a, 2b, 
2c, 2d, 2e, 2g, 2h, 2j and 2k. So, eight compounds were active against both cultures 
E.Coli and S.Paratyphi B. i.e. 2a, 2b, 2c, 2d, 2e, 2g, 2h and 2k. At the conc. 250 
µg/ml E.Coli was not killed by any compound (2a-k). S.Paratyphi B. was also 
inhibited by five compounds 2b, 2c, 2d, 2h and 2k. So, it is obvious from the data 
obtained that compounds 2b, 2c, 2d, 2h and 2k was highly active among all the 
compounds of series 2a-k. 
 
 For fungi in the series 2a-k almost seven compounds 2a, 2b, 2d, 2g, 2h and 2k 
were found active at 500 µg/ml conc. against A.niger. C. albicans was inhibited at 
500 µg/ml conc. by seven compounds i.e. 2a, 2b, 2d, 2e, 2g, 2h and 2k. At the conc. 
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of 250 µg/ml C.albicans was not killed by any compounds (2a-k). A. Niger was not 
killed any compounds (2a-k).  
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SECTION-III 
 
Preparation, Characterisation and Antimicrobial Evaluation Of 4-(Substituted 
Thiophenoxy)-3-Nitro-N-[6-{4-Oxo-3,4-Dihydro-1’H-Spiro-(Chromene-2,4’- 
piperidin)-1’-yl} Pyridine-3-yl]-Benzamides.  
Keeping in view of wide spectrum biodynamic activities[1-39]  of Pyridine and 
with a view to have potent therapeutic agents, the synthesis of 4-(substituted 
thiophenoxy)-3-nitro-N-[6-{4-oxo-3,4-dihydro-1’H-Spiro-(chromene-2,4’-piperidi 
n)-1’-yl}pyridine-3-yl] benzamides (3a-k) have been synthesized by the 
nucleophilic substitution of the chloro atom of  4-chloro, 3-nitro- N-[6-{4-oxo-3,4 
dihydro-1’H- spiro-(chromene-2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides with 
different substituted thiophenols. 
 
 
 
 
 
                
                           
(3a-k) 
                    R= Substituted thiophenoxy 
The constitution of the synthesized products (3a-k) have been characterized 
by using elemental analyses, infrared and 1H nuclear magnetic resonance 
spectroscopy and further supported by mass spectrometry. Purity of all 
compounds has been checked by thin layer chromatography.        
All the compounds have been evaluated for their antibacterial activity against 
Gram Positive bacteria like Staphylococcus aureus, Bacillus subtilis and 
Gram Negative bacteria like Escherichia coli, Salmonella peratyphi B and 
they were also evaluated for antifungal activity against Candida albicans and 
Aspergillus niger at different concentrations: i.e. Primary screening at 2000 
to 1000, Secondary screening at 1000 to 250 and tertiary screening at 250 to 
3.9 (µg/ml) for their MIC (Minimum Inhibitory Concentration) values. The 
antimicrobial activities of the synthesized compounds (3a-k) have been 
N
O
O
N
NH
O
R
N
+
O
-
O
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compared with standard drugs. Their antimicrobial effect was determined in 
higher dilution using Agar Dilution Method (Approved by NCCLs). 
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REACTION SCHEME 
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N
O
O
NH
O
NO2
Cl
N
N
O
O
NH
O
NO2
R
(Scaffold- A)
substituted Thiophenols
DMF, t-BuOK
R = Substituted Thiophenoxy
0°C-RT
(3a-k)
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EXPERIMENTAL 
Preparation, Characterization and antimicrobial evaluation of 4-(substituted 
Thiophenoxy)-3-nitro-N-[6-{4-oxo-3,4-dihydro-1’H-spiro-(chromene-2,4’-piperid 
in)-1’-yl} pyridine-3-yl]-benzamides. 
[A] Synthesis of Scaffold-A. 
For Preparation, see Part-I, Section-I, Page No. (29 to 31) 
[B] Synthesis of 4-(4’-Methoxy-1-thiophenoxy) -3-nitro-N-[6-{4-oxo-3, 4 dihydro-
1’H- spiro (chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides. 
In RBF, Scaffold-A (1.00 mol) in DMF and Potassium tert-Butoxide (1.10 mol) 
was added at room temperature. Then reaction mixture was allowed to cool at 0°C. In 
reaction mixture, 4-methoxythiophenol was added at 0°C and reaction mixture was 
allowed to warm at room temperature and stirred for 1 hours. Then reaction mixture 
was quenched with water to get solid. The solid was filtered under vacuum and 
washed with water. The solid was triturating with ethanol to get pure product. M.P.-
212°C. Elemental Analysis: Calculated: C (64.42%), H (4.73%), N (9.39%), Found: C 
(64.38%), H (4.70%), N (9.35%). 
Similarly, other compounds (3a-k) were synthesized by above mentioned process 
[B] from Scaffold-A. The physical data are recorded in Table-III. 
 
[C] Antimicrobial activity of 4-(substituted Thiophenoxy) -3-nitro-N-[6-{4-oxo-3, 
4 dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-
benzamides. 
Antimicrobial activity testing was carried out as described in Part-I, Section-I, Page 
No. (32 to 36) The MIC values of test solution are recorded in Table NO-3a and 3b. 
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TABLE NO-3: Physical constants of 4-(substituted Thiophenoxy) -3-nitro-N-[6-
{4-oxo-3, 4 dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-
benzamides (3a-k). 
Sr. 
No. 
Substitution 
R 
Molecular 
Formula/ 
Molecular weight 
M.P. 
°C 
Yield 
% 
% Composition
Calcd./Found 
C H N 
3a 
O
S
 
C32H28N4O6S 
596 
212  68 
64.42 
64.38 
4.73 
4.70 
9.39 
9.35 
3b 
S
 
C31H26N4O5S 
566 
102  80 
65.71 
65.56 
4.62 
4.47 
9.89 
9.75 
3c 
S
Br  
C31H25BrN4O5S 
645 
139  70 
57.68 
57.52 
3.90 
3.81 
8.68 
8.54 
3d 
S
N
+
O
-
O  
C31H25N5O7S 
611 
181  35 
60.88 
60.63 
4.12 
3.93 
11.45 
11.09 
3e  S
O
CH3
 
C32H28N4O6S 
596 
129  74 
64.42 
64.27 
4.73 
4.42 
9.39 
9.23 
3f 
S
CH3  
C32H28N4O5S 
580 
194  65 
66.19 
66.09 
4.86 
4.59 
9.65 
9.49 
3g  NH
N
N
+
O
-
O
S
 
C32H25N7O7S 
651 
191  70 
58.98 
58.79 
3.87 
3.72 
15.05 
14.69 
3h 
S
CH3
 
C32H28N4O5S 
580 
162  66 
66.19 
65.83 
4.86 
4.71 
9.65 
9.43 
3i 
SCH3
 
C32H28N4O5S 
580 
187  70 
66.19 
65.92 
4.86 
4.76 
9.65 
9.42 
3j 
SO
CH3
 
C32H28N4O6S 
596 
168  71 
64.42 
64.21 
4.73 
4.61 
9.39 
9.22 
3k 
S
Cl  
C31H25ClN4O5S 
601 
190  60 
61.94 
61.70 
4.19 
4.05 
9.32 
9.20 
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IR Spectral Study of 4-(4’-Methoxy-1-thiophenoxy) -3-nitro-N-[6-{4-oxo-3, 4 
dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides 
(3a). 
  
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:  4000-
400 cm-1 (KBr disc.) 
Type Vibration Mode Frequency in cm-1 Ref. No. 
Observed Reported  
Alkane  -C-H asym. str. 
-C-H sym. str. 
-C-H asym. def. 
-C-H sym. Def.  
2926
2830
1464
1292
2975-2850 
2900-2800 
1460-1400 
1385-1300 
  42 
  42 
  42 
  42 
Aromatic 
 
-C-H str. 
-C=C- ring skeleton 
 
p-disubstituted benzene 
3065
1516
1464
835
3090-3010 
1600-1450 
1600-1450 
850-800 
  42 
  44 
  44 
  44 
Pyridine 
moiety 
-C=N Str. 
-C-N- Str. 
-C-NO2 asym. Str. 
1610
1302
1530
1690-1570 
1310-1250 
1570-1500 
  43 
  43 
  43 
spirochromene 
moiety 
-C-O-C asym. Str. 
-C-O-C sym. Str. 
Cyclic  -C=O str. 
1251
1047
1682
1250-1200 
1050-1010 
1740-1630 
  42 
  42 
  42 
Amide  -C=O str. 
N-H str. 
1655
3350
1740-1630 
3400-3200 
  42 
  43 
40060080010001200140016001800200024002800320036004000
1/cm
30
40
50
60
70
80
90
100
%T
29
26
.1
1
16
81
.9
8
16
54
.9
8
16
10
.6
1
15
16
.1
0
14
64
.0
2
12
92
.3
5
12
51
.8
4
12
28
.7
0
11
76
.6
2
11
18
.7
5
10
47
.3
8
97
9.
87
91
6.
22
83
5.
21
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N
O
N
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O
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O
S
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1H-NMR Spectral Study of 4-(4’-Methoxy-1-thiophenoxy) -3-nitro-N-[6-{4-oxo-
3, 4 dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-
benzamides (3a).  
O
N
N
NH
O
S
O
O
NO 2
ab
c
d
e
f
g
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 Instrument: BRUKER 400 MHz (Avance - II), Internal reference: TMS,  
Solvent: 
DMSO-
d6Serial No. 
Signal 
position  
(δ ppm) 
Relative No. 
of Protons 
Multiplicity Inference 
1 1.74 2H Triplate -(CH2) a 
2 1.94 2H Triplate -(CH2) b, 
3 2.874 2H Singlet -(CH2) c 
4 3.29 2H Triplate -(CH2) d 
5 3.85 3H Singlet -(CH3) e 
6 3.98 2H Triplate -(CH2) f 
7 6.905-8.842 14H Complex Ar -H 
16 10.36 1H Singlet -(NH) g 
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Mass Spectral Study of 4-(4’-Methoxy-1-thiophenoxy) -3-nitro-N-[6-{4-oxo-3, 4 
dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides 
(3a). 
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Possible Mass Fragmentation pattern: 
N
O
NO2
N
H
O
O
N
H
O
O
m/z= 170
m/z= 212
m/z= 217
m/z= 412 m/z= 516 m/z= 491
m/z= 552
m/z= 335
m/z= 546
m/z= 141+
.°
+
°
+ +
+
+
+
+
++
° °
°
°
°
°
°
°
m/z= 596 (M+)
N
O
N
NH
O
NO2
O
S
O
SH
O
N
O
N
NH
O
NO2
O
S
O
N
O
N
NH
O
O
N
O
N
NH
O
O
S
O
N
O
N
NH
O
O
SH
NO2
N
NH
O
S
O
NO2
N
O
N
NH
O
O
S
O +°
m/z= 105 basepeak
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CONCLUSION 
ANTIMICROBIAL ACTIVITY 
 
The newly synthesized organic compounds were screened through three different 
types of screening i.e. (1) Primary Screening using 2000 µg/ml conc. (2) Secondary 
Screening 1000 µg/ml to 250 µg/ml conc. (3) Tertiary Screening start from 125 µg/ml 
to 3.9 µg/ml. The compounds which were active against the microbes in primary 
screening were taken for the secondary screening. The compounds which gave 
inhibition of microbes in secondary screening were further analyzed in tertiary 
screening. 
 From the results of experiments using newly synthesized organic compounds’ 
it is clear that all the compounds were moderately active at lower dilution i.e. high 
concentration like 2000 µg/ml and 1000 µg/ml conc. of compounds. In the series 3a-k 
almost four compounds 3a, 3b, 3e and 3i were found active at 500 µg/ml conc. against 
staphylococcus aureus. Bacillus Subtilis was inhibited at 500 µg/ml conc. by eight 
compounds 3a, 3b, 3d, 3e, 3f, 3g, 3i and 3j. Four compounds 3a, 3b, 3e and 3i were 
active against both cultures B.Subtilis and S.aureus. At the conc. 250 µg/ml S. aureus 
was not killed by any compounds (3a-k). B.Subtilis was inhibited by three compounds 
3b, 3e and 3i. So, it is obvious from the data obtained that compounds 3b, 3e and 3i 
were highly active among all the compounds of series 3a-k. 
 For Gram Negative bacteria in the series 3a-k almost six compounds 3a, 3b, 
3d, 3e, 3g and 3i were found active at 500 µg/ml conc. against Escherichia Coli. 
S.Paratyphi B. was inhibited at 500 µg/ml conc. by eight compounds i.e.  3a, 3b, 3d, 
3e, 3f, 3g, 3i and 3j. So, six compounds were active against both cultures E.Coli and 
S.Paratyphi B. i.e. 3a, 3b, 3d, 3e, 3g and 3i. At the conc. 250 µg/ml E.Coli was killed 
by two compounds i.e. 3e and 3i. S.Paratyphi B. was also inhibited by two 
compounds 3e and 3i. So, it is obvious from the data obtained that compounds 3e and 
3i was highly active among all the compounds of series 3a-k. 
 For fungi in the series 3a-k almost nine compounds 3a, 3b, 3c, 3d, 3e, 3g, 3i, 
3j and 3k were found active at 500 µg/ml conc. against A.niger. C. albicans was 
inhibited at 500µg/ml conc. by eight compounds i.e. 3a, 3b, 3c, 3d, 3e, 3g, 3i and 3j. 
At the conc. of 250µg/ml C.albicans was not killed by any compounds (3a-k). A. 
Niger was not killed by any compounds (3a-k). 
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SECTION-IV 
 
Preparation, Characterization and antimicrobial evaluation of 4-(substituted 
phenyl)-3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro-(chromene-2,4’-piperidin)-
1’-yl}pyridine-3-yl]-benzamides. 
 Keeping in view of wide spectrum biodynamic activities[1-39] of 
Pyridine and with a view to have potent therapeutic agents, the synthesis of 
4-(substituted aryl)-3-nitro-N-[6-{4-oxo-3,4-dihydro-1’H-spiro-(chromene-2,4’-
piperidin)-1’-yl}pyridine-3-yl]-benzamides (4a-k) have been synthesized by the 
nucleophilic substitution of the chloro atom of  4-chloro 3-nitro- N-[6-{4-oxo-3,4 
dihydro-1’H- spiro-(chromene-2,4’- piperidin)-1’-yl}pyridine-3-yl]-benzamides with 
different substituted phenyl boronic acids. 
 
 
 
 
 
                
 
                   
(4a-k) 
                                                               R= Aryl 
The constitution of the synthesized products (4a-k) have been 
characterized by using elemental analyses, infrared and 1H nuclear magnetic 
resonance spectroscopy and further supported by mass spectrometry. Purity 
of all compounds has been checked by thin layer chromatography.        
All the compounds have been evaluated for their antibacterial activity against 
Gram Positive bacteria like Staphylococcus aureus, Bacillus subtilis and 
Gram Negative bacteria like Escherichia coli, Salmonella peratyphi B and 
they were also evaluated for antifungal activity against Candida albicans and 
Aspergillus niger at different concentrations: i.e. Primary screening at 2000 
to 1000, Secondary screening at 1000 to 250 and tertiary screening at 250 to 
3.9 (µg/ml) for their MIC (Minimum Inhibitory Concentration) values. The 
antimicrobial activities of the synthesized compounds (4a-k) have been 
N
O
O
N
NH
O
R
N
+
O
-
O
Pyridyl Spiro Derivatives…  
Part-1 (Section-IV)… 
 
76
compared with standard drugs. Their antimicrobial effect was determined in 
higher dilution using Agar Dilution Method (Approved by NCCLs). 
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REACTION SCHEME 
 
 
N
N
O
O
NH
O
NO2
Cl
N
N
O
O
NH
O
NO2
R
(Scaffold- A)
Substituted Phenyl 
Boronic acids
Toluene,
Ethanol, Water
Pd-Tetrakis
R = Aryl
75°C
3 Hours
(4a-k)
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EXPERIMENTAL 
 
Preparation, Characterization and antimicrobial evaluation of 4-(substituted 
phenyl) -3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-
1’-yl} pyridine-3-yl]-benzamides. 
[A] Synthesis of Scaffold-A. 
For Preparation, see Part-I, Section-I, Page No. (29 to 31) 
[B] Synthesis of 4-(2-fluoro phenyl) -3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- spiro 
(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides. 
In RBF, Scaffold-A (1.00 mol) in Toluene and Pd-Tetrakis (0.10 mol) was added 
at room temperature under nitrogen purging. In reaction mixture, Ethanol, Water, 2-
fluoro PhenylBoronic acid (1.10 mol) and K2CO3 (2.5 mol) was added at room 
temperature under nitrogen purging and stirred for 20 minutes at same conditions. 
Then reaction mixture heated at 75°C temperature for 3-4 hours. Then reaction 
mixture was allowed to cool at room temperature and quenched with water. The 
product was extracted with ethyl acetate. The organic layer was washed with brine 
solution, dried over sodium sulphate and concentrated under reduced pressure to get 
crude product. The crude product was purified by using column chromatography. The 
product was eluted at 40-45% ethyl acetate in hexane. Yield: 35%  M.P.- 206°C. 
Elemental Analysis: Calculated: C (67.38%), H (4.56%), N (10.14%), Found: C 
(67.21%), H (4.41%), N (10.01%). 
Similarly, other compounds (4a-k) were synthesized by above mentioned process 
[B] from Scaffold-A. The physical data are recorded in Table-4. 
 
[C] Antimicrobial activity of 4-(substituted phenyl) -3-nitro-N-[6-{4-oxo-3, 4 
dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides. 
Antimicrobial activity testing was carried out as described in Part-I, Section-I, Page 
No. (32 to 36) The MIC values of test solution are recorded in Table NO-4a and 4b. 
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TABLE NO-4: Physical constants of 4-(substituted phenyl) -3-nitro-N-[6-{4-oxo-
3, 4 dihydro-1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-
benzamides (4a-k). 
Sr. 
No. 
Substitution 
R 
Molecular 
Formula/ 
Molecular 
weight 
M.P. 
°C 
Yield 
% 
% Composition
Calcd./Found 
C H N 
4a 
F
 
C31H25FN4O5 
552 
206  35 
67.38 
67.21 
4.56 
4.41 
10.14 
10.01 
4b 
O
CH3
 
C32H28N4O6 
564 
217  50 
68.07 
67.82 
5.00 
4.91 
9.92 
9.79 
4c 
CH3
CH3 
C33H30N4O5 
562 
111  45 
70.45 
70.28 
5.37 
5.24 
9.96 
9.81 
4d  CH3
CH3
CH3
 
C35H34N4O5 
590 
120  50 
71.17 
71.01 
5.80 
5.69 
9.49 
9.38 
4e 
CH3
CH3
 
C33H30N4O5 
562 
115  42 
70.45 
70.26 
5.37 
5.33 
9.96 
9.86 
4f 
N
 
C32H25N5O5 
559 
143  30 
68.69 
68.52 
4.50 
4.42 
12.52 
12.43 
4g 
N
+
O
-
O
 
C31H25N5O7 
579 
120  55 
64.24 
64.09 
4.35 
4.23 
12.08 
11.91 
4h 
N+
O
-
O
 
C31H25N5O7 
579 
135  52 
64.24 
64.07 
4.35 
4.26 
12.08 
11.96 
4i 
O
CH3
 
C32H28N4O6 
564 
174  50 
68.07 
67.83 
5.00 
4.86 
9.92 
9.83 
4j 
F
 
C31H25FN4O5 
552 
192  40 
67.38 
67.23 
4.56 
4.47 
10.14 
10.06 
4k 
Cl
 
C31H25ClN4O5 
569 
201  40 
65.44 
65.28 
4.43 
4.36 
6.23 
6.14 
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IR Spectral Study of 4-(2’-fluoro phenyl) -3-nitro-N-[6-{4-oxo-3, 4 dihydro-1’H- 
spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides (4a). 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:  4000-
400 cm-1 (KBr disc.) 
 
Type Vibration Mode Frequency in cm-1 Ref. No. 
Observed Reported  
Alkane -CH2 -C-H asym. str. 
-C-H sym. Str. 
-C-H asym. def. 
-C-H sym. Def.  
2929
2852
1462
1359
2975-2850 
2900-2800 
1460-1400 
1385-1300 
42 
42 
42 
42 
Aromatic -C-H str. 
-C=C- ring skeleton 
 
C-H o.o.p. def. (sym.) 
3040
1525
1460
758
3090-3010 
1600-1450 
1600-1450 
800-750 
42 
44 
44 
      44 
Pyridine 
moiety 
-C=N str. 
-C-N str. 
1613
1311
1690-1570 
1310-1250 
43 
43 
Chromanone 
moiety 
C-O-C asym. Str. 
C-O-C sym. Str. 
Cyclic -C=O str. 
1257
1109
1730
1250-1200 
1050-1010 
1740-1650 
42 
42 
42 
Amide Ketone -C=O str. 1668 1740-1650 42 
 
 
 
40060080010001200140016001800200024002800320036004000
1/cm
20
30
40
50
60
70
80
90
100
%T
29
29
.9
7
28
52
.8
1
17
30
.2
1
16
68
.4
8
16
12
.5
4
15
25
.7
4
14
60
.1
6
13
69
.5
0
13
11
.6
4
12
57
.6
3
12
20
.9
8
11
09
.1
1
98
3.
73
92
2.
00
81
9.
77
75
8.
05
57
2.
88
RJ-7.
N
O
N
NH
O
NO2
O
F
Pyridyl Spiro Derivatives… 
Part-1 (Section-IV)… 
81
1H-NMR Spectral Study of 4-(2-fluoro phenyl) -3-nitro-N-[6-{4-oxo-3, 4 dihydro-
1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides (4a). 
 
 
 
 
 
N
O
N
NH
O
O
O
NO2
F
a
b
c
d
e
f
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Instrument: BRUKER 400 MHz (Advance - II), Internal reference: TMS, 
Solvent: DMSO-d6 
 
  
Serial 
No. 
Signal Position(δ 
ppm)  
 
Relative 
No. of 
Protons 
Multiplicity Inference 
 
1 1.721-1.794 2H Multiplate -(CH2) a 
2 1.959-1.992 2H Multiplate -(CH2) b, 
3 2.883 2H Singlet -(CH2) c 
4 3.285-3.312 2H Multiplate -(CH2) d 
5 3.987-4.020 2H doublet -(CH2) e 
6 6.959-8.657 14H Complex Ar -H 
7 10.53 1H Singlet -(NH) o 
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Mass Spectral Study of 4-(2-fluoro phenyl) -3-nitro-N-[6-{4-oxo-3, 4 dihydro-
1’H- spiro-(chromene-2, 4’- piperidin)-1’-yl} pyridine-3-yl]-benzamides (4a). 
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Possible Mass Fragmentation pattern: 
N
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m/z= 170
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m/z= 296 m/z= 506
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CONCLUSION 
ANTIMICROBIAL ACTIVITY 
 
 The newly synthesized organic compounds were screened through three 
different types of screening i.e. (1) Primary Screening using 2000 mg/ml conc. (2) 
Secondary Screening 1000 mg/ml to 250 mg/ml conc. (3) Tertiary Screening start 
from 125 mg/ml to 3.9 mg/ml. The compounds which were active against the 
microbes in primary screening were taken for the secondary screening. The 
compounds which gave inhibition of microbes in secondary screening were further 
analyzed in tertiary screening. 
 
 From the results of experiments using newly synthesized organic compounds’ 
it is clear that all the compounds were moderately active at lower dilution i.e. high 
concentration like 2000 µg/ml and 1000 µg/ml conc. of compounds. In the series 4a-k 
almost eight compounds 4a, 4b, 4d, 4e, 4f, 4h, 4i and 4k were found active at 500 
µg/ml conc. against staphylococcus aureus. Bacillus Subtilis was inhibited at 500 
µg/ml conc. by eight compounds 4a, 4b, 4d, 4e, 4f, 4h, 4i and 4k. Eight compounds 
4a, 4b, 4d, 4e, 4f, 4h, 4i and 4k were active against both cultures B.Subtilis and 
S.aureus. At the conc. 250 µg/ml S. aureus was not inhibited by any compounds. 
B.Subtilis was killed by two compounds 4a and 4d (4a-k). So, it is obvious from the 
data obtained that compounds 4a and 4d were highly active among all the compounds 
of series 4a-k. 
 
 For Gram Negative bacteria in the series 4a-k almost eight compounds 4a, 4b, 
4c, 4d, 4f, 4h, 4i and 4k were found active at 500 µg/ml conc. against Escherichia 
Coli. S.Paratyphi B. was inhibited at 500 mg/ml conc. by eight compounds i.e.  4a, 
4b, 4c, 4d, 4f, 4h, 4i and 4k  So, eight compounds were active against both cultures 
E.Coli and S.Paratyphi B. i.e. 4a, 4b, 4c, 4d, 4f, 4h, 4i and 4k. At the conc. 250 µg/ml 
E.Coli was killed by three compounds i.e.  4a, 4b and 4h (4a-k). S.Paratyphi B. was 
also inhibited by three compounds i.e. 4a, 4f and 4h. So, it is obvious from the data 
obtained that compounds 4a and 4h was highly active among all the compounds of 
series 4a-k. 
 
 For fungi in the series 4a-k almost nine compounds 4a, 4b, 4c, 4d, 4f, 4g, 4h, 
4i and 4k were found active at 500 mg/ml conc. against A.niger. C. albicans was 
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inhibited at 500 µg/ml conc. by nine compounds i.e. 4a, 4b, 4c, 4d, 4e, 4f, 4h, 4i and 
4k. At the conc. of 250 mg/ml C.albicans was not killed by any compound. A. Niger 
was killed by one compound i.e. 4b. So, it is obvious from the data obtained that 
compound 4b was highly active among all the compounds of series 4a-k. 
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Part-II (Pyrimidylspiro derivatives) 
INTRODUCTION 
2-Piperazino-pyrimidine derivatives bearing spiro piperidine derivatives and their 
biological importance. 
The influenza virus, especially the H5N1 strain of influenza A, is a serious threat to 
human health. The outbreak of highly pathogenic H5N1 avian influenza virus in 1997 
and 2004/5 caused the death of millions of chickens and had a very high mortality rate 
among the limited number of infected humans. These cases cause great concern about the 
transmission of avian virus mutants among humans. The spread of influenza virus is 
mainly due to two factors: antigenic drift and antigenic shift. [1] 
The AM2 proton channel plays an important role in viral replication by facilitating 
uncoating of the virus after its endocytosis into the host cells. The low pH of the 
endosome activates the AM2 channel, thus allowing proton flux into the viral interior. 
This acidification dissociates the viral RNA from its bound matrix proteins, [2] a process 
that is required to release the viral genetic material to the cytoplasm for replication. [3] 
 
Amantadine targets AM2 by blocking the acidification of the virus entrapped in 
endosomes. Unfortunately the use of amantadine-related drugs is limited by central 
nervous system (CNS) side effects and the rapid emergence of drug-resistant viruses such 
as L26F, V27A, A30T, and S31N.[4-5] Extensive structure-activity relationship (SAR) 
studies of adamantly derivatives [6-8] have been evaluated, leading to a series of potent 
adamantine analogues active against H2N2 and H3N2 viruses. 
 
 
However, few other molecular scaffolds have been explored, which led to search for 
novel scaffolds that might provide new avenues for developing antagonists of AM2. The 
spirene guanidine analogue, 2-[3-azaspiro(5,5)undecanol]-2-imidazoline (BL-1743), is 
discovered through a high-throughput screen based on the ability of inhibitors to reverse 
the toxicity associated with M2 channels expressed in the yeast Saccharomyces 
cerevisiae membranes.[9] 
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Exploration of G-protein-coupled receptor (GPCR) ligands in drug discovery is an 
outstanding subject in constant progress in today’s pharmaceutical research. [11] Several 
motives have been identified in the structure of GPCR ligands. These moieties are 
referred to “privileged structures” and have successfully been utilized for the design of 
novel ligands. [12] Within the known “privileged structures”, spiropiperidines have 
provided potent agonists and antagonists for different biological GPCR targets. [13] 
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The generation of a compound library consisting of a spiropyrrolo-pyrrole as a privileged 
GPCR scaffold and the 3, 5-bis (trifluoromethyl) phenyl motive as a neurokinin-1 specific 
needle is described. A series of nanomolar activities are disclosed. [14] 
 
N
NN
OO
R
R'
IF3C
CF3
GPCR- scaffold NK-1 needle
R
 
 
 
Similarly, the generation of a compound library consisting of spirohydantoin as a privileged 
GPCR scaffold and the 3, 5-bis (trifluoromethyl) phenyl motive as a neurokinin-1 specific 
needle is described. A series of nanomolar actives are disclosed. [15] 
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Bedos et al synthesized a potent and selective B1 bradykinin receptor antagonist, JMV1645 
(H-Lys- Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH), containing a dipeptide mimetic ((3S)-amino-
5-carbonylmethyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (D-BT) moiety) at the C-
terminal. Analogues of this potent B1 bradykinin receptor antagonist in which the central 
Pro2-Hyp3-Gly4-Igl5 tetrapeptide has been replaced by constrained N-1-substituted-1, 3, 8-
triazaspiro [4.5] decan-4-one ring system were synthesized. Among these analogues, 
compound JMV1640 (1) was found to have an affinity of 24.10 ± 9.48 nM for the human 
cloned B1 receptor. It antagonized the [des-Arg10]-kallidin-induced contraction of the human 
umbilical vein (pA2 = 6.1 ± 0.1). Compound 1 was devoid of agonist activity at the kinin B1 
receptor. Moreover, it did not bind to the human cloned B2 receptor. Therefore, JMV1640 
constitutes a lead compound for the rational search of nonpeptide B1 receptor analogues 
based on the BK sequence. [16] 
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Felie et al reported solid support synthesis of spiroimidazolones. This methodology allowed 
the preparation of 8-benzyl-4-(p-substituted-benzyl)-1,4,8-triazaspiro[4.5]decan-2-ones 1 and 
2-(8-benzyl-2-oxo-1,4,8-triazaspiro[4.5]dec-1-yl)acetamides 2 from Rink amide lanterns.  
The key step of the synthesis was the formation of the spiroimidazolidinone system which 
was performed by condensation of N-benzyl-4-piperidone onto amino acid amides 3 and 
dipeptides 4 linked to the solid support, respectively. This step was accomplished after a 
reaction time of 10 days for the preparation of compounds 1, whereas it was completed after 
24 h for the synthesis of compounds 2. Although in both strategies, the HPLC purities and 
yields of the spiroimidazolidinones were satisfactory, the long reaction time was the limiting 
factor of the process. [17] 
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Tuberculosis (TB) caused by Mycobacterium tuberculosis bacteria (MTB) a is one of the 
most prevalent diseases that is responsible for the deaths of about one billion people during 
the last two centuries. TB remains a serious public health problem in India, accounting for 
nearly one-third of the global burden, and it has been estimated that 3.5 million of the 
population are infected with TB. [18] Hence, the discovery of fast-acting effective new drugs 
to effectively combat TB, including multidrug resistant tuberculosis, is imperative. 
Kumar et al reported atom economic and stereoselective synthesis of several spiro-piperidin-
4-ones through 1,3-dipolar cycloaddition of azomethine ylides generated in situ from isatin 
and R-amino acids viz. proline, phenylglycine, and sarcosine to a series of 1-methyl-3,5-
bis[(E)- arylmethylidene]tetrahydro-4(1H)-pyridinones. These compounds were evaluated 
for their in vitro and in vivo activity against Mycobacterium tuberculosis H37Rv (MTB), 
multidrug resistant Mycobacterium tuberculosis (MDR-TB) and Mycobacterium smegmatis 
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(MC2). Compound 4-(4-fluorophenyl)-5-phenylpyrrolo(spiro[2.3′′]oxindole)spiro[3.3′]-1′-
methyl-5′-(4-fluorophenyl ethylidene) piperidin-4′-one was found to be the most active in 
vitro with a MIC value of 0.07 µM against MTB and was 5.1 and 67.2 times more potent 
than isoniazid and ciprofloxacin, respectively. In vivo, compound decreased the bacterial 
load in lung and spleen tissues with 1.30 and 3.73-log 10 protections respectively and was 
considered to be promising in reducing bacterial count in lung and spleen tissues. [19] 
US7, 557,117 relates to 4-oxoimidazolidine-2-spiropiperidine derivatives represented 
by a general formula [I] 
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In which A1, A2, A3, A4 and A5 stand for optionally halogen-substituted methine, or 
nitrogen atom. 
These compounds act as nociceptin receptor agonist, and are useful as analgesic, 
reliever from tolerance to narcotic analgesic, reliever from dependence on narcotic analgesic, 
analgesic enhancer, antiobestic, drug for ameliorating brain function, remedy for 
schizophrenia, drug for treating regressive neurodegenerative diseases, antianxiety agent or 
antidepressant and remedy for diabetes insipidus and polyuria. [20] 
It also describes use of the compounds or salts thereof for formulating pharmaceutical 
compositions adequate for analgesic purpose; relief from tolerance to narcotic analgesic 
represented by morphine; relief from dependence on narcotic analgesic represented by 
morphine; enhancing analgesic action, treating obesity; improving brain function; treating 
antianxiety or antidepression; treating diabetes insipidus; treating polyuria; treating 
hypotension; anesthesia or assisting anesthesia; remedy for sleep disorders represented by 
insomnia including increased sleep latency, intermittent wakefulness and decreased sleep 
efficiency; remedy for circadian rhythm disorder such as jet lag; drug for improving erectile 
function; airway dilation during dyspenea such as asthma or antitussive; or as drug for 
ameliorating motility of digestive tract during hypokinesis of digestive tract. methods for 
pain- killing, relief from tolerance to narcotic analgesic represented by morphine; relief from 
dependence on narcotic analgesic represented by morphine; enhancing analgesic action, 
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treating obesity; improving brain function; treating schizophrenia. 
Antianxiety or antidepression; treating diabetes insipidus; treating polyuria; treating 
hypotension; anesthesia or assisting anesthesia; remedy for sleep disorders represented by 
insomnia including increased sleep latency, intermittent wakefulness and decreased sleep 
efficiency; remedy for circadian rhythm disorder such as jet lag; drug for improving erectile 
function; airway dilation during dyspenea such as asthma or antitussive; or as drug for 
ameliorating motility of digestive tract during hypokinesis of digestive tract, which are 
characterized by administering the compounds or salts thereof to patients: and a method for 
producing 4-oxoimidazolidine-2-spiropiperidine derivatives or salts thereof. 
 Padmavathi et al report new class of spiro-pyrimidinones, pyrazolidinones and 
isoxazolidinones prepared from 4-cyano-4-ethoxycarbonyl-piperidines / tetrahydropyrans / 
tetrahydrothiopyrans [21]. 
US2008/0004261 provides CGRP receptor antagonists, pharmaceutical compositions thereof, 
and methods therewith for treating CGRP receptor-mediated diseases and conditions.CGRP 
(Calcitonin Gene-Related Peptide) is a naturally occurring 37-amino acid peptide that is 
generated by tissue- specific alternate processing of calcitonin messenger RNA and is widely 
distributed in the central and peripheral nervous system. CGRP is localized predominantly in 
sensory afferent and central neurons and mediates several biological actions, including 
vasodilation. CGRP is expressed in alpha- and beta- forms that vary by one and three amino 
acids in the rat and human, respectively. CGRP-alpha and CGRP-beta display similar 
biological properties. When released from the cell, CGRP initiates its biological responses by 
binding to specific cell surface receptors that are predominantly coupled to the activation 
origin. 
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The compounds of the present invention have utility in treating, preventing, ameliorating, 
controlling or reducing the risk of one or more of the following conditions or diseases: 
headache; migraine; cluster headache; chronic tension type headache; pain; chronic pain; 
neurogenic inflammation and inflammatory pain; neuropathic pain; eye pain; tooth pain; 
diabetes; non-insulin dependent diabetes mellitus; vascular disorders; inflammation; arthritis; 
bronchial hyperreactivity, asthma; shock; sepsis; opiate withdrawal syndrome; morphine 
tolerance; hot flashes in men and women; allergic dermatitis; encephalitis; brain trauma; 
epilepsy; neurodegenerative diseases; skin diseases; neurogenic cutaneous redness, skin 
rosaceousness and erythema; tinnitus; inflammatory bowel disease, irritable bowel syndrome, 
cystitis; and other conditions that may be treated or prevented by antagonism of CGRP 
receptors. Particular importance is the acute or prophylactic treatment of headache, including 
migraine and cluster headache. [22] 
The nociceptin (NOP) receptor is the latest identified member of the transmembrane G-
protein coupled receptors family comprising d, k and m opioid receptors.[23] 
 
Its original homology cloning and the isolation from brain extracts of the endogenous ligand, 
the heptadecapeptide nociceptin (NC), [24, 25] gave rise to a great interest in clarifying its 
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physiological functions. The receptor, distributed in both central and peripheral nervous 
systems and in non-neuronal tissues, revealed to be involved in several processes including 
modulation of nociception, locomotor activity, reversal of stress-induced analgesia, [26] 
modulation of learning and memory, [27-29] regulation of neurotransmitter and hormone 
release, [30, 31] neuronal differentiation.[32, 33] 
 
In the last years NOP receptor has become an important biological target for a number of 
potential therapeutic applications associated with pain, stress and anxiety, cognitive 
deficiency, eating and other disorders. [34] At the same time, consistent advances have been 
attained in the design and discovery of new ligands, and many nonpeptide small molecules 
were developed as agonists or antagonists. [35-39] 
 
Among several scaffolds, spiropiperidines showed to be an interesting and promising 
class of NOP ligands. They are structurally related to lofentanyl, a m -selective opiate ligand 
having also affinity for the NOP receptor. 
 
The NOP active site [40, 41] was first investigated by computational studies on its 
complex with nociceptin [42, 43] and lofentanyl Anyway spiropiperidines [44] were useful tools 
for the elucidation of the mechanism of interaction of small non peptidic molecules. These 
studies indicated the electrostatic interaction of protonated piperidinic nitrogen with Asp130 
and a hydrogen bond between the small molecule and Thr305 as determinant features for 
affinity. 
 
US7705042 describes compounds that inhibit protein tyrosine kinases, especially c-
fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory 
component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon 
cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, 
including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, 
inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other 
diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, 
osteolytic sarcoma, myeloma, and tumor metastasis to bone using these compounds. These 
compounds also includes 2-piperazine pyrimidine derivatives. [45] 
 
 
Pyrimidine Derivatives 
Part-II (Introduction) 101
 
N
N
H
N
N
N
Cl
NO2
N
N
N
NO2
N
N
+
 
 
Illig et al describe reduction of nitro derivative to get amino compound. [46] 
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Discovery of a series of novel 2,4-disubstituted arylamides as potential anti-
inflammatory agents is also describes in this paper. 
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US2003/0078271 reports compounds which are selective antagonists for the GAL3 
receptor. [47] 
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Thus, spiro piperidine and 2-piperazino pyrimidine forms very interesting pharmaceutical 
scaffolds. These compounds show very promising biological activity for variety of 
therapeutic category. Various research papers and patents, as discussed above describes 
different modifications to this scaffold and their effect on their potency as therapeutic 
agents. 
 
Current work:- 
Current work provides the modifications to spiro piperidine scaffold. 
 
N
N
N
NH N
N
NH
O
O
O
 
 
This scaffold is reacted with following reactants 
ClO
SO O
Cl
R R
 
 
Wherein R stands for various substitutions describe in experimental sections. Synthesized 
compounds are characterized by spectral analyses. These compounds can display the 
pharmacological activities as their previous structurally related compounds do. 
    S       
         The work is further subdivided into following sections. 
1) Preparation, Characterization and antimicrobial evaluation of Ethyl -2-(4-Substituted 
benzoylpiperazin-1-yl)-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine -
5-carboxylate 
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2) Preparation, Characterization and antimicrobial evaluation of Ethyl -2-[4-(Sub stituted 
benzenesulfonyl) piperazin-1-yl]-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) 
pyrimidine -5-carboxylates. 
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SECTION-I 
 
Preparation, Characterization and antimicrobial evaluation of Ethyl -2-(4-
Substituted benzoylpiperazin-1-yl)-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] 
dec-8-yl) pyrimidine-5-carboxylate. 
 Keeping in view of wide spectrum biodynamic activities[1-48] of 
Pyrimidine and with a view to have potent therapeutic agents, the synthesis 
of Ethyl -2-(4-Substituted benzoylpiperazin-1-yl)-4-(1-phenyl-3-oxo-1, 4, 8-
triazaspiro [4, 5] dec-8-yl) pyrimidine -5-carboxylate (1a-k) have been 
synthesized by the using Ethyl 2-(piperazin-1-yl) 4-(1-phenyl-3-oxo-1,4,8-
triazaspiro [4,5] dec-8-yl ) pyrimidine -5-carboxylate with different substituted 
benzoyl chlorides. 
N
N
N
N
N
NH N
O
O
OCH3
O
R
 
(1a-k) 
                                                              R= Aryl 
 
   The constitution of the synthesized products (1a-k) have been 
characterized by using elemental analyses, infrared and 1H nuclear magnetic 
resonance spectroscopy and further supported by mass spectrometry. Purity 
of all compounds has been checked by thin layer chromatography.     
All the compounds have been evaluated for their antibacterial activity 
against Gram Positive bacteria like Staphylococcus aureus, Bacillus subtilis 
and Gram Negative bacteria like Escherichia coli, Salmonella peratyphi B 
and they were also evaluated for antifungal activity against Candida albicans 
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and Aspergillus niger at different concentrations: i.e. Primary screening at 
2000 to 1000, Secondary screening at 1000 to 250 and tertiary screening at 
250 to 3.9 (µg/ml) for their MIC (Minimum Inhibitory Concentration) values. 
The antimicrobial activities of the synthesized compounds (1a-k) have been 
compared with standard drugs. Their antimicrobial effect was determined in 
higher dilution using Agar Dilution Method (Approved by NCCLs). 
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REACTION SCHEME 
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EXPERIMENTAL 
Preparation, Characterisation and antimicrobial evaluation of Ethyl-2-(4-
Substitutedbenzoylpiperazine-1-yl)-4-(1-phenyl-3-oxo-1, 4, 8-triazaspir [4, 5] dec-
8-yl) pyrimidine -5-carboxylate. 
 [A] Synthesis of Scaffold-B. 
1. Synthesis of Ethyl -2-(methylthio)-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] 
dec-8-yl) pyrimidine -5-carboxylate (Intermediate-3). 
In RBF, 4-phenyl-1, 4, 8-triazaspiro [4.5] decan-2-one (1.10mol) and DMF (10 
times) were charged. K2CO3 (2.50mol) and ethyl 4-chloro (methylsulfonyl) 
pyrimidine-5-carboxylate (1.00mol) was added at 0°C. Then reaction mixture was 
allowed to warm at room temperature and stirred for 4-5 hours.  After the completion 
of reaction, Reaction mixture was quenched in crushed ice. The product was extracted 
with Dichloromethane. The organic phase was washed with 1N HCl, brine solution 
and dried over sodium sulfate. The organic phase was concentrated under reduce 
pressure at 45°C to get desired product. Yield: 62.00 % M.P: 203°C. Elemental 
Analyses: Calculated: C (59.00%), H (5.89%), N (16.38%), Found: C (58.75%), H 
(5.62%), N (16.12%). 
2. Synthesis of Intermediate-4. 
In RBF, Intermediate-3 (1.00mol) was dissolved in Dry MDC.  Then reaction 
mixture is allowed to cool at 0°C. M-chloro per benzoic acid (2.50mol) was added 
portion wise in to the reaction mixture at 0°C. Then reaction mixture was allowed to 
stirr at same temperature for 30 minutes. After the completion of reaction, reaction 
mixture was quenched with saturated sodium bicarbonate solution. The product was 
extracted with Dichloromethane and organic layer was washed with brine solution. 
The organic phase was dried over sodium sulphate and concentrated under reduce 
pressure at 45°C to get crude product which was purified by triturating with diethyl 
ether. Yield: 70.00 %. M.P: 213°C. Elemental Analyses: Calculated: C (54.89%), H 
(5.48%), N (15.24%), Found: C (54.6%), H (5.23%), N (15.03%). 
 
3. Synthesis of Ethyl -2-(piperazine)-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] 
dec-8-yl) pyrimidine -5-carboxylate. (Scaffold-B) 
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In RBF, Intermediate-4 (1.00mol) and piperazine (2.00mol) were dissolved in THF at 
room temperature. The reaction mixture was heated to 60°C temperature for 2 hours. 
After the completion of reaction, reaction mixture was quenched in water. The 
product was extracted with Chloroform, washed with saturated sodium bicarbonate 
solution. The organic phase was dried over sodium sulphate and concentrated under 
reduce pressure at 45°C to get crude product. The crude product was purified by using 
column chromatography. Yield: 40.00 %. M.P: 189°C. Elemental Analyses: 
Calculated: C (61.92%), H (6.71%), N (21.06%), Found: C (61.52%), H (6.30%), N 
(20.45%). 
[B] Synthesis of Ethyl -2-(4- benzoylpiperazin-1-yl)-4-(1-phenyl-3-oxo-1, 4, 8-
triazaspiro [4, 5] dec-8-yl) pyrimidine -5-carboxylate. 
In RBF, Scaffold-B (1.00mol) in THF and K2CO3 (2.50mol) was added at room 
temperature. Then reaction mixture was cooled to 0°C.  In reaction mixture, the 
benzoyl chloride (1.10mol) solution in THF was added at 0°C and reaction was 
allowed to warm at room temperature and stirred for 1 hour. Then solvent was 
removed under vacuum at 45°C. The residue obtained was quenched with water to get 
solid. The solid was triturating with diethyl ether to get pure product. Yield: 52.00 %. 
M.P: 144°C. Elemental Analyses: Calculated: C (65.36%), H (6.19%), N (17.21%), 
Found: C (61.31%), H (6.13%), N (17.16%). 
Similarly, other compounds (1a-k) were synthesized by above mentioned process 
(B) from Scaffold-B. The physical data are recorded in Table-1. 
 
[C] Antimicrobial activity of Ethyl -2-(4-Substituted benzoylpiperazin-1-yl)-4-(1-
phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine -5-carboxylate. 
Antimicrobial activity testing was carried out as described in Part-I, Section-I, Page 
No. (32 to 36) The MIC values of test solution are recorded in Table NO-1a and 1b. 
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TABLE NO-1: Physical constants of Ethyl-2-(4-Substituted benzoylpiperazin-1-
yl)-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine-5-arboxylates 
(1a-k). 
Sr. 
No. 
Substitution 
R 
Molecular 
Formula/ 
Molecular weight 
M.P. 
°C 
Yield 
% 
% Composition
Calcd./Found 
C H N 
1a 
 
C31H35N7O4 
569 
144  52 
65.36 
65.31 
6.19 
6.13 
17.21 
17.16 
1b 
C H 3  
C32H35ClN6O4 
603 
115  54 
63.73 
63.68 
5.85 
5.81 
13.93 
13.89 
1c 
CH3
 
C34H40N6O4 
596 
157  48 
68.43 
68.39 
6.76 
6.71 
14.08 
14.03 
1d 
CH3
 
C37H46N6O4 
638 
162  52 
69.57 
69.53 
7.26 
7.23 
13.16 
13.11 
1e 
F
F
 
C32H34F2N6O4 
604 
107  52 
63.56 
63.51 
5.67 
5.59 
13.90 
13.83 
1f  O
CH3
 
C33H38N6O5 
598 
132  58 
66.20 
66.13 
6.40 
6.33 
14.04 
14.02 
1g  OH
 
C32H36N6O5 
584 
156  42 
65.74 
65.69 
6.21 
6.17 
14.37 
14.32 
1h 
O
CH3
 
C33H38N6O5 
598 
175  56 
66.20 
66.14 
6.40 
6.35 
14.04 
14.01 
1i 
O
CH3
 
C33H38N6O5 
598 
152  56 
66.20 
66.11 
6.40 
6.36 
14.04 
14.00 
1j  F
 
C32H35FN6O4 
586 
162  44 
65.51 
65.46 
6.01 
5.96 
14.33 
14.29 
1k  N+
O
-
O
 
C32H35N7O6 
613 
109  48 
62.63 
62.59 
5.75 
5.71 
15.98 
15.93 
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IR Spectral Study of Ethyl -2-(4-Substituted benzoylpiperazin-1-yl)-4-(1-phenyl-
3-oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine -5-carboxylate (1a).
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:  4000-
400 cm-1 (KBr disc.) 
Type Vibration Mode Frequency in cm-1 Ref. No
Observed Reported (Part-I) 
Alkane -CH2 C-H asym. str.    
C-H sym. str. 
C-H asym. def. 
C-H sym. Def. 
2933
2862
1427
1354
2975-2850 
2900-2800 
1460-1400 
1385-1300 
    42 
    42 
    42 
    42 
Aromatic C-H str. 
C=C ring skeleton 
C-H o.o.p. def. (sym.) 
3030
1521
1485
694
3080-3010 
1600-1450 
1600-1450 
740-670 
42 
44 
44 
44 
Imidazolone 
moiety 
-N-H-str (2° amine) 
-N-H-def  
-C=O str. (cyclic keto) 
3330 
1577 
1740 
3410-3300 
1650-1550 
1740-1650 
43 
43 
43 
Pyrimidine 
moiety 
C-N str. 
C-N str. Def 
1620
1261
1635-1595 
1340-1250 
43 
43 
Ester  
 
-C=O str. 
C-O-C assym. Str. 
C-O-C sym. Str. 
1713
1226
1089
1740-1650 
1250-1200 
1050-1010 
42 
42 
42 
Benzylic 
ketone 
-C=O str. 1690 1740-1650 42 
  
40060080010001200140016001800200024002800320036004000
1/cm
0
15
30
45
60
75
90
105
120
135
%T
29
76
.2
6
29
33
.8
3
28
74
.0
3
17
12
.8
5
16
89
.7
0
15
77
.8
2 1
52
1.
89
14
85
.2
4
14
27
.3
7
13
73
.3
6
13
54
.0
7
12
94
.2
8
12
61
.4
9
12
26
.7
7
11
99
.7
6
11
63
.1
1
10
89
.8
2
69
4.
40
63
6.
53
53
4.
30
51
1.
15
45
5.
22
RJJ-1
N
N
N
NH N
O
N
N
O
O
O
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1H-NMR Spectral Study of Ethyl -2-(4-benzoylpiperazin-1-yl)-4-(1-phenyl-3-
oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine -5-carboxylate (1a) 
N
N
N
NH N
N
N O
O
OCH3
O
a
b
cc
d
d
e
f
f
g
h
i
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6
 
 
 
Instrument: BRUKER 400 MHz (Advance ‐ II), Internal reference: TMS, Solvent: DMSO‐d6.  
Sr. No 
Signal Position  
(δ ppm) 
Relative 
No. of 
Protons 
Multiplicity Inference 
1 1.15-1.24 3H Triplate -(CH3) a 
2 1.638-1.673 2H Doublet -(CH2) b 
3 2.566 4H Singlate -(CH2)2 c 
4 3.095 4H Singlate -(CH2)2 d 
5 3.438-3.560 2H Triplate -(CH2)  e 
6 3.854 4H Singlate -(CH2)2 f 
7 4.153-4.206 2H Quartrate -(CH2)  g 
8 4.603 2H Singlate -(CH2)  h 
9 6.59-8.442 11H Complex Ar-H  
10 8.785 1H Singlet -(NH) i 
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Mass Spectral Study of Ethyl -2-(4-benzoylpiperazin-1-yl)-4-(1-phenyl-3-oxo-1, 4, 
8-triazaspiro [4, 5] dec-8-yl) pyrimidine -5-carboxylate (1a). 
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CONCLUSION 
ANTIMICROBIAL ACTIVITY 
 
 The newly synthesized organic compounds were screened through three 
different types of screening i.e. (1) Primary Screening using 2000 µg/ml conc. (2) 
Secondary Screening 1000 µg/ml to 250 µg/ml conc. (3) Tertiary Screening start from 
125 µg/ml to 3.9 mg/ml. The compounds which were active against the microbes in 
primary screening were taken for the secondary screening. The compounds which 
gave inhibition of microbes in secondary screening were further analyzed in tertiary 
screening. 
 From the results of experiments using newly synthesized organic compounds’ 
it is clear that all the compounds were moderately active at lower dilution i.e. high 
concentration like 2000 µg/ml and 1000 µg/ml conc. of compounds. In the series 1a-k 
almost all compounds were found active at 500 µg/ml conc. against staphylococcus 
aureus. Bacillus Subtilis was inhibited at 500 µg/ml conc. by all compounds 1a to 1k. 
Eleven compounds 1a to 1k were active against both cultures B.Subtilis and S.aureus. 
At the conc.250 µg/ml S. aureus was inhibited by two compounds 1b and 1g. 
B.Subtilis was killed by one compound 1e. So, it is obvious from the data obtained 
that compounds 1b, 1e and 1g were highly active among all the compounds of series 
1a-k. 
 For Gram Negative bacteria in the series 1a-k almost five compounds 1d, 1e, 
1g, 1h and 1j were found active at 500 µg/ml conc. against Escherichia Coli. 
S.Paratyphi B. was inhibited at 500 µg/ml conc. by four compounds i.e.  1a, 1e, 1g, 
and 1j. So, three compounds were active against E.Coli and S.Paratyphi B. i.e. 1e, 1g 
and 1j. At the conc. 250 µg/ml E.Coli was not killed by any compound (1a-k). 
S.Paratyphi B. was not inhibited by any compound (1a-k). So, it is obvious from the 
data obtained that compounds 1e, 1g and 1j was highly active among all the 
compounds of series 1a-k. 
 For fungi in the series 1a-k almost four compounds i.e.  1d, 1e, 1g, and 1j were 
found active at 500 µg/ml conc. against A.niger. C. albicans was inhibited at 500 
µg/ml conc. by four compounds i.e. 1d, 1e, 1g, and 1j. At the conc. of 250 µg/ml 
C.albicans was not killed by any compounds (1a-k). A. Niger was not killed by any 
compounds (1a-k). So, it is obvious from the data obtained that compounds 1d, 1e, 1g, 
and 1j was highly active among all the compounds of series 1a-k. 
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SECTION-II 
 
Preparation, Characterization and antimicrobial evaluation of Ethyl -2-[4-(Sub 
stituted benzenesulfonyl) piperazin-1-yl]-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 
5] dec-8-yl) pyrimidine -5-carboxylates. 
 Keeping in view of wide spectrum biodynamic activities[1-48] of 
Pyrimidine and with a view to have potent therapeutic agents, the synthesis 
of Ethyl -2-[4-(Substituted benzenesulfonyl) piperazin-1-yl]-4-(1-phenyl-3-oxo-1, 
4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine-5-carboxylates (2a-k) have been 
synthesized by the using Ethyl 2-(piperazin-1-yl) 4-(1-phenyl-3-oxo-1,4,8-
triazaspiro [4,5] dec-8-yl ) pyrimidine -5-carboxylate with different substituted phenyl 
sulfonyl chlorides. 
N
N
N
N
N
NH N
O
O
OCH3
S
O
O
R
 
   (2a-k) 
                                                               R= Aryl 
 
The constitution of the synthesized products (2a-k) have been 
characterized by using elemental analyses, infrared and 1H nuclear magnetic 
resonance spectroscopy and further supported by mass spectrometry. Purity 
of all compounds has been checked by thin layer chromatography.     
All the compounds have been evaluated for their antibacterial activity against 
Gram Positive bacteria like Staphylococcus aureus, Bacillus subtilis and 
Gram Negative bacteria like Escherichia coli, Salmonella peratyphi B and 
they were also evaluated for antifungal activity against Candida albicans and 
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Aspergillus niger at different concentrations: i.e. Primary screening at 2000 
to 1000, Secondary screening at 1000 to 250 and tertiary screening at 250 to 
3.9 (µg/ml) for their MIC (Minimum Inhibitory Concentration) values. The 
antimicrobial activities of the synthesized compounds (2a-k) have been 
compared with standard drugs. Their antimicrobial effect was determined in 
higher dilution using Agar Dilution Method (Approved by NCCLs). 
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REACTION SCHEME 
 
N
N
O
O N
NH N
O
N
NH
Scaffold-B
THF, K2CO3
0 °C to RT
Step-A R
SO O
Cl
N
N
O
O N
NH N
O
N
N
S
O
O R  
(2a‐k) 
R= Aryl 
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EXPERIMENTAL 
Preparation, Characterization and antimicrobial evaluation of Ethyl-2-[4-
(Substituted benzenesulfonyl) piperazin-1-yl]-4-(1-phenyl-3-oxo-1, 4, 8-triaza 
spiro [4, 5] dec-8-yl) pyrimidine -5-carboxylates. 
 [A] Synthesis of Scaffold-B. 
For Preparation, see Part-II, Section-I, Page No. (109 & 110) 
[B] Synthesis of Ethyl -2-[4-O-toluene sulfonyl) piperazin-1-yl]-4-(1-phenyl-3-
oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine -5-carboxylates. 
In RBF, Scaffold-B (1.00 mol) in THF and K2CO3 (2.50 mol) was added at room 
temperature. Then reaction mixture was cooled to 0°C.  In reaction mixture, o-toluene 
sulphonyl chloride (1.10mol) solution in THF was added at 0°C and reaction was 
allowed to warm at room temperature and stirred for 1-2 hours. Then solvent was 
removed under vacuum at 45°C. The residue obtained was quenched with water to get 
solid. The solid was triturating with diethyl ether to get pure product. Yield: 42.00 %. 
M.P: 102°C. Elemental Analyses: Calculated: C (62.12%), H (6.19%), N (13.58%), 
Found: C (62.03%), H (6.11%), N (13.47%). 
Similarly, other compounds (2a-k) were synthesized by above mentioned process 
(B) from Scaffold-B. The physical data are recorded in Table-2. 
 
[C] Antimicrobial activity of Ethyl -2-[4-(Substituted benzenesulfonyl) piperazin-
1-yl]-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine -5-
carboxylates. (2a-k) 
Antimicrobial activity testing was carried out as described in Part-I, Section-I, Page 
No. (32 to 36) The MIC values of test solution are recorded in Table NO-2a and 2b. 
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TABLE NO-2: Physical constants of Ethyl -2-[4-(Substituted benzenesulfonyl) 
piperazin-1-yl]-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine -
5-carboxylates (2a-k). 
Sr. 
No. 
Substitution 
R 
Molecular 
Formula/ 
Molecular weight 
M.P. 
°C 
Yield 
% 
% Composition
Calcd./Found 
C H N 
2a 
CH3
 
C32H38N6O5S 
618 
102  42 
62.12 
62.03 
6.19 
6.11 
13.58 
13.47 
2b  CH3
CH3  
C32H40N6O5S 
632 
207  44 
62.64 
62.47 
6.37 
6.29 
13.28 
13.19 
2c  Br
 
C31H35BrN6O5S 
683 
225  38 
54.47 
54.32 
5.16 
5.11 
12.29 
12.21 
2d 
 
C31H36N6O5S 
604 
223  54 
61.57 
61.39 
6.00 
5.89 
13.90 
13.79 
2e  N
F  
C32H34FN7O5S 
647 
209  30 
59.34 
59.13 
5.29 
5.21 
15.14 
15.03 
2f  CH3
 
C32H38N6O5S 
618 
111  48 
62.12 
62.04 
6.19 
6.11 
13.58 
13.48 
2g  CH3
 
C32H38N6O5S 
618 
117  47 
62.12 
62.01 
6.19 
6.10 
13.58 
13.46 
2h  N+
O
-
O
 
C31H35N7O7S 
649 
152  46 
57.31 
57.09 
5.43 
5.34 
15.09 
15.01 
2i  N+
O
-
O  
C31H35N7O7S 
649 
168  44 
57.31 
57.14 
5.43 
5.36 
15.09 
15.00 
2j  O
CH3
 
C32H38N6O6S 
634 
142  52 
60.55 
60.29 
6.03 
5.88 
13.24 
13.12 
2k 
O CH3
 
C32H38N6O6S 
634 
207  54 
60.55 
60.31 
6.03 
5.87 
13.24 
13.09 
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IR Spectral Study of Ethyl -2-[4-(2’-methyl benzenesulfonyl) piperazin-1-yl]-4-
(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5]dec-8-yl) pyrimidine-5-carboxylates. (2a)
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:  4000-
400 cm-1 (KBr disc.) 
Type Vibration Mode Frequency in cm-1 Ref. No. 
Observed Reported (Part -1) 
Alkane -CH2 C-H asym. str.    
C-H sym. str. 
C-H asym. def. 
C-H sym. Def. 
2916
2862
1444
1354
2975-2850 
2900-2800 
1460-1400 
1385-1300 
42 
42 
42 
42 
Aromatic C-H str. 
C=C ring skeletal 
 
C-H o.o.p. def. (sym.) 
3010
1535
1502
720
3080-3010 
1600-1450 
1600-1450 
740-670 
42 
44 
44 
44 
Imidazolone 
moiety 
-N-H-str (2° amine) 
-N-H-def  
-C=O str. (cyclic keto) 
3330
1581
1730
3410-3300 
1650-1550 
1740-1650 
43 
43 
42 
Pyrimidine 
moiety 
Sulfonyl 
group 
C-N str. 
C-N str. Def 
-SO assy.str 
-SO sym.str 
1605
1240
1311
1163
1635-1595 
1340-1250 
1350-1300 
1160-1120 
43 
43 
44 
44 
Ester  
 
-C=O str. 
C-O-C assym. Str. 
C-O-C sym. Str. 
1709
1226
1093
1740-1650 
1250-1200 
1050-1010 
42 
42 
42 
40060080010001200140016001800200024002800320036004000
1/cm
10
20
30
40
50
60
70
80
90
100
%T
29
82
.0
5
29
16
.4
7
28
62
.4
6
17
08
.9
9
15
81
.6
8
15
35
.3
9
15
02
.6
0
14
44
.7
3
13
54
.0
7
13
11
.6
4
12
40
.2
7
12
26
.7
7
11
63
.1
1
10
93
.6
7 97
2.
16
74
2.
62
0
59
0.
24
20
.8
0
46
6.
79
22
RJK-1
N
N
N
NH N
O
N
N
O
O
S
O
O
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6
1H-NMR Spectral Study of Ethyl -2-[4-(Substituted benzenesulfonyl) 
piperazin-1-yl]-4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) 
pyrimidine -5-carboxylates (2a-k). 
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   Instrument: BRUKER 400 MHz (Advance ‐ II), Internal reference: TMS, Solvent: DMSO‐d6.  
Sr. No 
Signal Position  
(δ ppm) 
Relative No. 
of Protons 
Multiplicity Inference
1 1.16 3H Triplate -(CH3)  
2 1.66 2H Doublet -(CH2)  
3 2.34 5H Multiplate -(CH2)3  
4 2.60 2H Multiplate -(CH2)  
5 2.91 4H singlet -(CH3)  
6 3.57 2H Triplate -(CH2)  
7 3.87 4H Singlate -(CH2)2   
8 4.23 2H Quartrate -(CH2)   
9 4.59 2H Singlate -(CH2)  
10  6.50-8.42 10H Complex  Ar -H   
11 8.79 1H Singlet -(NH)  
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Mass Spectral Study of Ethyl -2-[4-(2’-methyl benzenesulfonyl) piperazin-1-yl]-
4-(1-phenyl-3-oxo-1, 4, 8-triazaspiro [4, 5] dec-8-yl) pyrimidine -5-carboxylates 
(2a). 
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Possible Mass Fragmentation pattern: 
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CONCLUSION 
ANTIMICROBIAL ACTIVITY 
 
 The newly synthesized organic compounds were screened through three 
different types of screening i.e. (1) Primary Screening using 2000 µg/ml conc. (2) 
Secondary Screening 1000 µg/ml to 250 µg/ml conc. (3) Tertiary Screening start from 
125 µg/ml to 3.9 µg/ml. The compounds which were active against the microbes in 
primary screening were taken for the secondary screening. The compounds which 
gave inhibition of microbes in secondary screening were further analyzed in tertiary 
screening. 
 
 From the results of experiments using newly synthesized organic compounds’ 
it is clear that all the compounds were moderately active at lower dilution i.e. high 
concentration like 2000 µg/ml and 1000 µg/ml conc. of compounds. In the series 2a-k 
almost eight compounds 2a, 2b, 2d, 2e, 2g, 2h, 2j and 2k were found active at 500 
µg/ml conc. against staphylococcus aureus. Bacillus Subtilis was inhibited at 500 
µg/ml conc. by all compounds (2a-k). Eight compounds 2a, 2b, 2d, 2e, 2g, 2h, 2j and 
2k were active against both cultures B.Subtilis and S.aureus. At the conc. 250 µg/ml 
S. aureus was not killed by any compounds (2a-k). B.Subtilis was not inhibited by 
three compounds i.e. 2d, 2g and 2h. So, it is obvious from the data obtained that 
compounds 2d, 2g and 2h were highly active among all the compounds of series 2a-k. 
 
 For Gram Negative bacteria in the series 2a-k almost all compounds (2a-k) 
was not killed at 500 µg/ml conc. against Escherichia Coli. S.Paratyphi B. was 
inhibited at 500 µg/ml conc. by three compounds i.e. 2b, 2g and 2h. 250 µg/ml E.Coli 
was not killed by any compound (2a-k). S.Paratyphi B. was killed by any compound 
(2a-k). So, it is obvious from the data obtained that all compounds were not active of 
series 2a-k. 
 
 For fungi in the series 2a-k almost all compounds 2a to 2k were found active 
at 500 µg/ml conc. against A.niger. C. albicans was inhibited at 500 µg/ml conc. by 
all compounds i.e. 2a to 2k. At the conc. of 250 µg/ml C.albicans was inhibited by 
five compounds i.e. 2a, 2d, 2e, 2g and 2h. A. Niger was inhibited by three compounds 
i.e. 2b, 2e and 2h. So, it is obvious from the data obtained that compound 2e and 2h 
was highly active among all the compounds of series IIa-k. 
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Part-III (Tetrahydrothieno [2, 3-C] pyridines) 
INTRODUCTION 
Thieno pyridine containing APIs 
Plavix (clopidogrel bisulfate) is a Thienopyridine class inhibitor of P2Y12 ADP 
platelet receptors. Chemically it is methyl (+)-(S)-α-(2-chlorophenyl)-6, 7-
dihydrothieno [3, 2-c] pyridine-5(4H) acetate sulfate (1:1). The structural formula is 
as follows: 
N
S
ClH
OO
.H2SO4
Clopidogrel  
Clopidogrel is an inhibitor of platelet activation and aggregation through the 
irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on 
platelets. Clopidogrel is a prodrug and is metabolized to a pharmacologically active 
metabolite and inactive metabolites. [1] 
Prasugrel is a new P2Y12 receptor antagonist that has been investigated for the 
treatment of atherothrombosis in patients with cardiovascular disease undergoing 
percutaneous coronary intervention (PCI). Similar to other Thienopyridine, prasugrel 
is a prodrug that requires biological conversion to active metabolites. [2]  
N
S
F
O
O
O
prasugrel  
In February 2009, the antiplatelet therapy prasugrel (Efient; Daiichi Sankyo/Eli Lilly) 
was granted marketing authorization by the European Commission for the prevention 
of atherothrombotic events in patients with acute coronary syndromes undergoing 
primary or delayed percutaneous coronary intervention. [3]  
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Ticlopidine (trade name Ticlid) is another drug in the thienopyridine family. Like 
clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. Combining 
either thienopyridine with an intravenous platelet IIb/IIIa inhibitor appears to be safe. 
[4]  
N
S
Cl
 
Biologically active Thieno pyridine compounds 
Andersen et al describes SAR study of Novel Selective and Orally Bioavailable 
Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 
1B. it provides a number of new chemical scaffolds for the development of inhibitors 
of different members of the PTP family. Although the core structure of these 
inhibitors is charged, good oral bioavailability has been observed in rat for some 
compounds. Furthermore, it was observed enhancement of 2-deoxy-glucose 
accumulation in C2C12 cells with prodrug analogues. [5]  
O OH
NH
O
OH
O
S
O OH
NH
O
OH
O
S
O OH
NH
O
OH
O
N
R
R R
 
Boschelli et al describes 7-[(2, 4-Dichloro-5-methoxyphenyl) amino] thieno [3, 2-b] 
pyridine-6-carbonitriles with various heteroaryl groups at C-2 are inhibitors of Src 
kinase activity. Of these new analogs, compounds substituted at C-2 by a 3,5-furan or 
a 2,5-pyridine had the best activity in the Src enzyme and cell assays. [6]  
N
S
NH
Cl Cl
O
CN
R
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Bernardino et al performed the design, synthesis, and the structure–activity 
relationship studies of 13 new derivatives of thieno [2, 3-b] pyridine. These 
derivatives were prepared in high yields (96–70%) and their structures were 
elucidated by IR, 1H, 13C NMR, and MS. The biological results showed some 
derivatives as antiparasitic agents against Giardia lamblia. Computational analysis of 
HOMO and LUMO energy, HOMO orbital coefficient distribution, electrostatic 
potential map, dipole moment, and density HOMO was performed to gain insight into 
the SAR aspects. [7]  
NS
NH
CN
R
R= H, m-CH3, p-CH3, m-OCH3, 
p-OCH3, m-NO2, p-NO2, m-F, 
p-F, m-Cl, p-Cl,m-Br, p-Br  
Tumey et al reports a series of 2-alkenyl thieno [2, 3-b] pyridine inhibitors of PKCθ 
were synthesized as potential inflammatory modulators. This series led to the 
discovery of 2-alkenyl amides, which are exceptionally potent and selective inhibitors 
of PKCθ. [8] 
NS
NH
CN
NH
O
N
PKC0 =3.8nM
PKCa, PKCb,PKCc,PKCd,PKCe> 1300nM  
Attaby et al describes reaction of thiocyanoacetamide with, β-unsatumted ketones 
resulted in the formation of the corresponding newly synthesized 1(H)pyridinethione 
derivatives. Compounds were used as synthons for the preparation of 2-S-alkyl-, 2-S-
aryl-, 2-S-acetamidopyridine, thieno[2,3-b]pyridine and pyrazolo[3,4-b]pyridine 
derivatives via a wide range of reactions with different reagents. The antimicrobial 
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activity of some of the newly synthesized compounds was tested. Few compounds 
were found to be the most active ones. [9] 
Tetra hydro Thieno pyridine derivatives are known as bioactive molecules since very 
long time. US4065460 (published in 1977) describes following thieno pyridine 
derivates as anti inflammatory and analgesic agents. [10] 
NH
S
R
1
OR
3
R
2
(I)
 
Compound of formula (I) is synthesized by cyclizing following intermediate. 
S
OR
3
R
1
R
2
N
 
Klinga et al N-4-aryl-piperazinyl-N′-ethyl-5, 6, 7, 8-tetrahydropyrido [4′, 3′:4, 5] 
thieno [2, 3-d] pyrimidin-4(3H)-one compounds as potential antidepressant 
drugs. [11] 
N
O
N
NS
N N
N
R
O
R=
1 2  
 
Thieno Pyridine Derivatives… 
Part-III (Introduction) 
 
141 
N
NH
O
Cl
OH
NS
N
N
O
OH
NS
N
N
O
N
N
O
Cl
OH
N S
O
O
NH2
+
NS
N
N
O
Cl
N S
O
O
NH2 OH
NH2
O
O
O
NS
N
N
O
OH
+ +
Reaction steps: 2
1.1: Acetic acid anhydride/ Heating
1.2: Ethanol/ Heating
1.3: SOCl2/ EDC/ 20°C
 
 
El-Kashef et al describes synthesis of Pyrido [4', 3’:4, 5] thieno [2, 3-d] pyrimidines 
and Related Heterocycles of biological importance. [12] 
US4076819 describes thieno-pyridine derivatives anti-inflammatory properties and 
inhibiting effects on blood plate aggregation which make them therapeutically 
valuable. 
NH S
OH
S
O
O
Cl
N S
S
OO
OH
ClH +
 
Toxicological investigation demonstrated the low toxicity and the good tolerance of 
the derivatives of this invention. The composition of this invention is usefully 
administrable for the treatment of the various stages of inflammation. It is applicable 
in chronic inflammatory rheumatism, degenerative rheumatism, in abarticular 
conditions, in oto-rhino-laryngology, in stomatology, in post-operative surgery and in 
traumatology. [13] 
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US6323214 relates to a compound of general formula 
(CH2)
Z S
O
R4R3
R2
NH
R1  
It also describes their use in medicine as allosteric adenosine receptor modulators for 
uses including protection against hypoxia and ischemia induced injury and treatment 
of adenosine-sensitive cardiac arrhythmias. [14] 
US2008/0146559 describes new 4,5,6,7-tetrahydro-thieno[2,3-c]pyridine derivatives, 
their manufacture, pharmaceutical compositions containing them and their use as 
medicaments. The active compounds of the invention are useful in treating obesity 
and other disorders.  [15] 
NS R
1
O
R
2
 
US2008/0146559 describes following structures. [16] 
S N
O
O
S O
N
S N
O
O
S O
N
S N
O
O
S O
N
S N
O
O
S O N
 
Recently the Thienopyridine derivatives are reported for various pharmacological 
activities e.g. [17-24].  
 
 
 
Thieno Pyridine Derivatives… 
Part-III (Introduction) 
 
143 
Current Work: 
Based on various tetra hydro Thienopyridine derivatives and their therapeutic 
importance, the present work provides newly tetra hydro Thienopyridine derivatives.  
These compounds are substituted with 4-methyl phenyl sulfonyl group on nitrogen 
atom, in Thienopyridine moiety. 
Various modifications are made to 2nd and 3rd position of thiophene ring to study 
effects of these substitutions on their activity. This can be summarized as below: 
Series A: In this series, compounds carry amide substitutions on 3rd position and 
Schiff base on 2nd position.  
Series B: Compounds of this series contains fused pyrimidine ring on 2nd and 3rd 
position. 
Series C: This series provides ester moiety on 3rd position and urea residue on 2nd 
position. 
Thus, the present work provides Thieno pyridine derivatives having various 
substitutions like amide, ester, urea and fused ring which can be used to study effects 
of these substitutions on their therapeutic activity. 
The present work also provides an efficient method for the synthesis of above 
biologically important derivatives. 
The work is further subdivided into following sections. 
1) Preparation, Characterization and antimicrobial evaluation of 2-(substituted 
benzyl ideneamino)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydrothieno 
[2, 3-c] pyridine-3-carboxamide. 
2) Preparation, Characterization and antimicrobial evaluation of 2-aryl-7-[(4-
methylphenyl)sulfonyl]-1,2,3,5,6,7,8-heptahydro pyrido[4',3': 4,5]thieno[2,3-
d] pyrimidin-4-ones. 
3) Preparation, Characterisation and antimicrobial evaluation of Ethyl-2-(3-
arylureido)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydro thieno [2, 3-c] 
pyridine-carboxylates. 
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SECTION-I 
 
Preparation, Characterization and antimicrobial evaluation of 2-(substituted 
benzyl ideneamino)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 
3-c] pyridine-3-carboxamide. 
 Keeping in view of wide spectrum biodynamic activities[1-26] of thieno 
pyridine  and with a view to have potent therapeutic agents, the synthesis of 2-
(substituted benzyl ideneamino)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-
tetrahydrothieno [2, 3-c] pyridine-3-carboxamide (1a-k) have been synthesized 
by using 2-(amino)-6-[(4-methylphenyl)sulfonyl]-4,5,6,7-tetrahydrothieno[2,3-
c]pyridine-3-carboxamide with differently substituted aromatic aldehydes. 
 
N
SS
CH3
O
O
NH2
N
O
R
 
(1a-k) 
                                                               R= Aryl 
The constitution of the synthesized products (1a-k) have been 
characterized by using elemental analyses, infrared and 1H nuclear magnetic 
resonance spectroscopy and further supported by mass spectrometry. Purity 
of all compounds has been checked by thin layer chromatography.        
 All the compounds have been evaluated for their antibacterial activity 
against Gram Positive bacteria like Staphylococcus aureus, Bacillus subtilis 
and Gram Negative bacteria like Escherichia coli, Salmonella peratyphi B 
and they were also evaluated for antifungal activity against Candida albicans 
and Aspergillus niger at different concentrations: i.e. Primary screening at 
2000 to 1000, Secondary screening at 1000 to 250 and tertiary screening at 
250 to 3.9 (µg/ml) for their MIC (Minimum Inhibitory Concentration) values. 
The antimicrobial activities of the synthesized compounds (1a-k) have been 
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compared with standard drugs. Their antimicrobial effect was determined in 
higher dilution using Agar Dilution Method (Approved by NCCLs). 
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REACTION SCHEME 
 
 
 
ClH
+
S OCl
O
S N OO
O
NH2
O
N
S N
O
O
S
NH2
O
NH2
S NO
O
S
NH2
O
NH2
R
O
N
H
O THF, TEA
3 hrs, RT
Step-1
ethanol, S
morpholine
Step-2
Acetic acid
RT
Step-3
(1) (2) (3) Scaffold-C
Scaffold-C (Ia-k)
R=  Aryl
S N
O
O
S
NH2
O
N
R
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EXPERIMENTAL 
Preparation, Characterisation and antimicrobial evaluation of 2-(substituted 
benzyl ideneamino)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 
3-c] pyridine-3-carboxamides. 
 [A] Synthesis of Scaffold-C. 
1.  Synthesis of 1-[(4-methylphenyl) sulfonyl]-4-piperidinone (Intermediate-3) 
In RBF, 4-piperidinone hydrochloride (1.00 mol), THF and Triethylamine (2.5 mol) 
were charged. The reaction mixture was cooled to 0°C and 4-methyl phenyl sulfonyl 
chloride (1.05mol) was added portion wise to the reaction mixture at 0°C. The 
reaction mixture was allowed to warm at room temperature and stirred for 4 hours at 
same temperature. After the completion of reaction, Reaction mixture was 
concentrated under reduced pressure at 45°C. The crude was quenched with chilled 
water and stirred for thirty minutes. The obtained solid was filtered and washed with 
water and dried. Yield: 85.00 %. M.P: 131°C, 1H NMR (solvent: CDCl3) δ 7.72 (d, 
2H, J=8.1 Hz), 7.38 (d, 2H, J=8.1 Hz) 3.42 (m, 4H), 2.58 (m, 4H), 2.42 (s, 3H). 
2. Synthesis of 2-amino-6-[(4-methylphenyl)sulfonyl]-4,5,6,7-tetrahydrothieno 
[2,3-c]pyridine-3-carboxamide (Scaffold-C). 
In RBF, 1-[(4-methylphenyl) sulfonyl]-4-piperidinone (1.0 mol) (Intermediate-3), 
2-cyano acetamide (1.10 mol), morpholine (5.0 mol) and sulfur (1.5 mol) was 
dissolved in ethanol at room temperature. The reaction mixture was heated at 70-80°C 
for 3-4 hours. After the completion of reaction, Reaction mixture was concentrated 
under reduced pressure at 45°C. The crude was quenched with chilled water and 
stirred for thirty minutes. The obtained solid was filtered and washed with water and 
dried. Yield: 75.00 %, M.P: 223°C. Elemental Analysis: Calculated: C (51.26%), H 
(4.88%), N (11.96%), Found: C (51.11%), H (4.67%), N (11.73%). 
 
[B] Synthesis of 2-(benzyl ideneamino)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-
tetrahydrothieno [2, 3-c] pyridine-3-carboxamide. 
In RBF, Scaffold-C (1.0 mol) in acetic acid were charged with benzaldehyde at 
room temperature. The reaction mixture was stirred for 1 hour at same temperature. 
After the completion of reaction, Reaction mixture was quenched with chilled water. 
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The obtained solid was filtered and washed with water and dried. The obtained 
product was purified by triturating with ethanol. Yield: 87.00 %, M.P: 202°C, 
Elemental Analysis: Calculated: C (60.11%), H (4.82%), N (9.56%), Found: C 
(60.05%), H (4.75%), N (9.42%). 
Similarly, other compounds (1a-k) were synthesized by above mentioned process 
(B) from Scaffold-C. The physical data are recorded in Table-1. 
 
[C] Antimicrobial activity of 2-(substituted benzyl ideneamino)-6-[(4-
methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 3-c] pyridine-3-
carboxamide. 
Antimicrobial activity testing was carried out as described in Part-I, Section-I, Page 
No. (32 to 36) The MIC values of test solution are recorded in Table NO-1a and 1b. 
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TABLE NO-1: Physical constants of 2-(substituted benzyl ideneamino)-6-[(4-
methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 3-c] pyridine-3-
carboxamide (1a-k). 
Sr. 
No.sc 
Substitution 
R 
Molecular 
Formula/ 
Molecular 
weight 
M.P. 
°C 
Yield 
% 
% Composition
Calcd./Found 
C H N 
1a  N
 
C23H20N4O3S2 
464 
258  73 
59.46 
59.20 
4.34 
4.26 
12.06 
11.80 
1b  F
 
C22H20N3O3S2F 
457 
185  76 
57.75 
57.40 
4.41 
4.29 
9.18 
9.02 
1c 
 
C22H21N3O3S2 
439 
202  87 
60.11 
59.92 
4.82 
4.65 
9.56 
9.42 
1d 
OCH3  
C23H23N3O4S2 
469 
204  87 
58.83 
58.65 
4.94 
4.81 
8.95 
8.83 
1e 
OH  
C22H21N3O4S2 
455 
220  84 
58.00 
57.74 
4.65 
4.53 
9.22 
9.09 
1f 
O
CH3
OH
 
C23H23N3O5S2 
485 
185  84 
56.89 
56.72 
4.77 
4.69 
8.65 
8.56 
1g 
N+
O-
O
 
C22H20N4O5S2 
484 
263  85 
54.53 
54.31 
4.16 
4.09 
11.56 
11.42 
1h 
OH  
C22H21N3O4S2 
455 
234  77 
58.00 
57.84 
4.65 
4.53 
9.22 
9.10 
1i 
Br  
C22H20N3O3S2Br 
518 
242  82 
50.97 
50.71 
3.89 
3.77 
8.11 
8.01 
1j 
OH
O
CH3
 
C23H23N3O5S2 
485 
220  78 
56.89 
56.62 
4.77 
4.65 
8.65 
8.52 
1k 
 
C26H23N3O3S2 
489 
209  83 
63.78 
63.49 
4.73 
4.56 
8.58 
8.49 
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IR Spectral Study of 2-(3’-hydroxy, 4’-methoxy benzyl ideneamino)-6-[(4-
methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 3-c] pyridine-3-
carboxamide(1i).
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:  4000-
400 cm-1 (KBr disc.) 
Type Vibration Mode Frequency in cm-1 Ref. No. 
Observed Reported (Part -1) 
Alkane -CH2 C-H asym. str. 
C-H sym. str. 
C-H asym. def. 
C-H sym. Def.  
2961
2847
1442
1336
2975-2850 
2900-2800 
1460-1400 
1385-1300 
42 
42 
42 
42 
Aromatic C-H str. 
C=C ring skeleton 
 
2951
1566
1508
3080-3010 
1600-1450 
1600-1450 
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3560
3338
1636
3600-3200 
3600-3200 
1740-1650 
43 
43 
42 
Ether C-O-C assym. Str. 
C-O-C sym. Str. 
1240
1028
1250-1200 
1050-1010 
42 
42 
Schieff’s base CH=N str. 1599 1650-1600 43 
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1H-NMR Spectra
[(4-methylphenyl
carboxamide (1i)
CH3
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N S
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O
N
NH2
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 Instrument: BRUKER 400 MHz (Advance - II), Internal reference: TMS, 
Solvent: DMSO- d6. 
Serial 
No. 
Signal Position  
(δ ppm) 
Relative No. 
of Protons 
Multiplicity Inference 
1 2.39 3H Singlet -(CH3) a 
2 2.885 2H Broad singlet -(CH2) b 
3 3.296 2H Triplet -(CH2) c 
4 3.854 3H Singlet -(CH3) d 
5 4.228 2H Singlet -(CH2) e 
6 7.063-7.722 7H Complex Ar -H 
7 8.171 1H Singlet -(N=CH) f 
8 8.407 1H Singlet -(NH) h 
9 9.516 2H Singlet -(OH) g 
 
  
Thieno Pyridine Derivatives… 
Part-III (Section-I) 
 
153
1HNMR spectra of 2-(4-bromo benzylidene amino)-6-[(4-methylphenyl) 
sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 3-c] pyridine-3-carboxamide (1j). 
 
 
 
 
 
CH3
S
N S
O
O
N
NH2 Br
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e
f
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Instrument: BRUKER 400 MHz (Advance - II), Internal reference: TMS, 
Solvent: DMSO- d6. 
 
Serial 
No. 
Signal Position 
(δ ppm) 
Relative No. 
of Protons 
Multiplicity Inference 
1 2.395 3H Singlet -(CH3) a 
2 2.850 2H Broad  singlet -(CH2) b 
3 3.278 2H Triplet -(CH2) c 
4 4.253 2H Singlet -(CH2) d 
5 7.431-7.890 8H Complex Ar -H 
6 7.965 1H Singlet -(N=CH) i 
7 8.571 2H Singlet -(NH) i 
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Mass Spectral Study of 2-(4-Hydroxy benzylidene amino)-6-[(4-methylphenyl) 
sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 3-c] pyridine-3-carboxamide (1h). 
S
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Possible Mass Fragmentation pattern: 
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CONCLUSION 
ANTIMICROBIAL ACTIVITY 
 
 The newly synthesized organic compounds were screened through three 
different types of screening i.e. (1) Primary Screening using 2000 µg/ml conc. (2) 
Secondary Screening 1000 µg/ml to 250 µg/ml conc. (3) Tertiary Screening start from 
125 µg/ml  to 3.9 µg/ml . The compounds which were active against the microbes in 
primary screening were taken for the secondary screening. The compounds which 
gave inhibition of microbes in secondary screening were further analyzed in tertiary 
screening. 
 
 From the results of experiments using newly synthesized organic compounds’ 
it is clear that all the compounds were moderately active at lower dilution i.e. high 
concentration like 2000 µg/ml and 1000 µg/ml conc. of compounds. In the series 1a-k 
almost eight compounds1a, 1b, 1c, 1d, 1f, 1g, 1i and 1j were found active at 500 
µg/ml conc. against staphylococcus aureus. Bacillus Subtilis was inhibited at 500 
µg/ml conc. by eight compounds 1a, 1b, 1c, 1d, 1f, 1i, 1j, and 1k. Seven compounds 
1a, 1b, 1c, 1d, 1f, 1i and 1j were active against both cultures B.Subtilis and S.aureus. 
At the conc. 250 µg/ml S. aureus was inhibited by four compounds 1c, 1f, 1i and 1j. 
B.Subtilis was inhibited by four compounds 1a, 1c, 1i and 1j. (1a-k). So it is obvious 
from the data obtained that compounds 1c, 1i and 1j were highly active among all the 
compounds of series 1a-k. 
 
 For Gram Negative bacteria in the series 1a-k almost six compounds 1a, 1c, 
1d, 1f, 1j and 1j were found active at 500 µg/ml conc. against Escherichia Coli. 
S.Paratyphi B. was inhibited at 500 µg/ml conc. by four compounds i.e. 1c, 1f, 1i and 
1j. So, four compounds were active against both cultures E.Coli and S.Paratyphi B. 
i.e. 1c, 1f, 1i and 1j. At the conc. 250 µg/ml E.Coli was not inhibited by one 
compound 1j (Ia-k). S.Paratyphi B. was also inhibited by one compound   1j. So, it is 
obvious from the data obtained that compound 1j was highly active among all the 
compounds of series 1a-k. 
 
 For fungi in the series 1a-k almost three compounds 1c, 1i and 1j were found 
active at 500 µg/ml conc. against A.niger. C. albicans was inhibited at 500 µg/ml 
conc. by six compounds i.e. 1c, 1i and 1j. At the conc. of 250 µg/ml C.albicans was 
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killed by one compound 1j. A. Niger was killed by one compound i.e. 1j. So, it is 
obvious from the data obtained that compound 1j was highly active among all the 
compounds of series 1a-k. 
Tetiory screening for Minimum Inhibitory Concentration: 
(Extensive investigation for the powerful antimicrobials of the series): 
Total nine series of synthesized organic compounds were analyzed for the 
Antibacterial and antifungal activity through primary and secondary screening using 
Agar Dilution Method. To get their exact MIC surprisingly compound 1j (R= 3-OH-
4-OCH3-C6H4) of series were highly active throughout the secondary screening. This 
compound was highly active and gave complete inhibition of E.Coli, S.Paratyphi B, 
B.Subtilis and S.aureus. Compound 1j (R= 3-OH-4-OCH3-C6H4) was highly active 
at 250 µg/ml conc. against fungal cultures A.niger and C. albicans. 
Then after this highly active compounds were used for tertiory screening 
against bacterial as well as fungal cultures. Compound 1j (R= 3-OH-4-OCH3-C6H4) 
was active for all bacterial cultures at 250 µg/ml conc. It was also very effective and 
gave complete inhibition of E.Coli, S.Paratyphi B at 125 µg/ml conc. 
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SECTION-II 
 
Preparation, Characterization and antimicrobial evaluation of 2-aryl-7-[(4-
methylphenyl) sulfonyl] -1,2,3,5,6,7,8—heptahydro pyrido[4',3': 4,5]thieno[2,3-d] 
pyrimidin-4-ones. 
 Keeping in view of wide spectrum biodynamic activities[5-26]  of thieno 
pyridine and with a view to have potent therapeutic agents, the synthesis of 2-
aryl-7-[(4-methylphenyl)sulfonyl]-1,2,3,5,6,7,8heptahydropyrido[4',3':4,5] thieno 
[2,3-d] pyrimidin-4-ones (2a-k) have been synthesized using 2-(amino)-6-[(4-
methylphenyl)sulfonyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide with 
different substituted aromatic aldehydes. 
N
SS
CH3
O
O
N
H
N
H
O
R
 
(2a-k) 
                                                               R= Aryl 
The constitution of the synthesized products (2a-k) have been 
characterized by using elemental analyses, infrared and 1H nuclear magnetic 
resonance spectroscopy and further supported by mass spectrometry. Purity 
of all compounds has been checked by thin layer chromatography.        
 All the compounds have been evaluated for their antibacterial activity 
against Gram Positive bacteria like Staphylococcus aureus, Bacillus subtilis 
and Gram Negative bacteria like Escherichia coli, Salmonella peratyphi B 
and they were also evaluated for antifungal activity against Candida albicans 
and Aspergillus niger at different concentrations: i.e. Primary screening at 
2000 to 1000, Secondary screening at 1000 to 250 and tertiary screening at 
250 to 3.9 (µg/ml) for their MIC (Minimum Inhibitory Concentration) values. 
The antimicrobial activities of the synthesized compounds (2a-k) have been 
compared with standard drugs. Their antimicrobial effect was determined in 
higher dilution using Agar Dilution Method (Approved by NCCLs). 
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REACTION SCHEME 
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EXPERIMENTAL 
Preparation, Characterization and antimicrobial evaluation of 2-aryl-7-[(4-
methylphenyl) sulfonyl]-1,2,3,5,6,7,8-heptahydropyrido[4',3': 4,5] thieno[2,3-d] 
pyrimidin-4-ones. 
[A] Synthesis of Scaffold-C. 
For Preparation, see Part-III, Section-I, Page No. 147  
[B] Synthesis of 2-(4-nitrophenyl)-7-[(4-methylphenyl) sulfonyl] 1, 2, 3, 5, 6, 7, 8 
heptahydropyrido [4, 3':4, 5] thieno [2, 3-d] pyrimidin-4-ones. 
In RBF, Scaffold-C (1.0 mol) in acetic acid were charged 4-nitrobenzaldehyde at 
room temperature. The reaction mixture was heated at reflux temperature for 5 hour. 
After the completion of reaction, Reaction mixture was cool at room temperature and 
quenched with chilled water. The obtaining solid was filtered and washed with water 
and dried. The obtained product was purified by triturating with ethanol. Yield: 
63.00%. M.P: 267°C. Elemental Analyses: Calculated: C (54.53%), H (4.16%), N 
(11.56%), Found: C (54.44%), H (4.11%), N (11.49%). 
Similarly, other compounds (2a-k) were synthesized by above mentioned process 
(B) from Scaffold-C. The physical data are recorded in Table-2. 
 
[C] Antimicrobial activity of 2-aryl-7-[(4-methylphenyl) sulfonyl] 1, 2, 3, 5, 6, 7, 8 
heptahydropyrido [4, 3':4, 5] thieno [2, 3-d] pyrimidin-4-ones. 
Antimicrobial activity testing was carried out as described in Part-I, Section-I, Page 
No. (32 to 36) The MIC values of test solution are recorded in Table NO-2a and 2b. 
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TABLE NO-2: Physical constants of 2-aryl-7-[(4-methylphenyl)sulfonyl]-
1,2,3,5,6,7,8heptahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-ones (2a-k). 
Sr. 
No. 
Substitution 
R 
Molecular 
Formula/ 
Molecular weight 
M.P. 
°C 
Yield 
% 
% Composition
Calcd./Found 
C H N 
2a 
N+
O-
O
 
C22H20N4O5S2 
484 
267  63 
54.53 
54.44 
4.16 
4.11 
11.56 
11.49 
2b 
 
C26H23N3O3S2 
489 
292  51 
63.78 
63.69 
4.73 
4.66 
8.58 
8.51 
2c 
OH
OH  
C22H21N3O5S2 
471 
272  68 
56.04 
55.91 
4.49 
4.42 
8.91 
8.82 
2d 
OH  
C22H21N3O4S2 
455 
252  68 
58.00 
57.81 
4.65 
4.59 
9.22 
9.14 
2e 
N
H  
C24H22N4O3S2 
478 
265  57 
60.23 
60.04 
4.63 
4.56 
11.71 
11.65 
2f 
F  
C22H20N3O3S2F 
457 
285  65 
57.75 
57.59 
4.41 
4.34 
9.18 
9.11 
2g  O
CH3 
C23H23N3O4S2 
469 
260  65 
58.83 
58.62 
4.94 
4.77 
8.95 
8.89 
2h 
O CH3
OH
 
C23H23N3O5S2 
485 
190  59 
56.89 
56.71 
4.77 
4.70 
8.65 
8.56 
2i 
N  
C23H20N4O3S2 
464 
278  58 
59.46 
59.31 
4.34 
4.28 
12.06 
11.93 
2j 
Cl  
C22H20N3O3S2Cl 
473 
282  66 
55.75 
55.53 
4.25 
4.14 
8.87 
8.76  
2k 
OH  
C22H21N3O4S2 
455 
293  66 
58.00 
57.81 
4.65 
4.57 
9.22 
9.13 
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IR Spectral Study of 2-(4-hydroxyphenyl)-7-[(4-methylphenyl)sulfonyl] 1, 2, 3, 5, 
6, 7, 8, heptahydropyrido [4',3':4,5]thieno[2,3-d]pyrimidin-4-ones (2d). 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer;  
Frequency range:  4000-400 cm-1 (KBr disc.) 
 
Type Vibration Mode Frequency in cm-1 Ref. No. 
Observed Reported (Part-I) 
Alkane -CH2 C-H asym. str. 
C-H asym. def. 
C-H sym. Def.  
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1600-1450 
42 
44 
44 
Thienopyridine 
moiety 
C-S-C str. 
C=N 
651
1635
700-650 
1650-1600 
44 
43 
Pyrimidone 
Cyclic amide 
-C=O str. 
-N-H str. 
1682
3420
1740-1650 
3600-3200 
42 
43 
Sulfonyl N-SO2 str. 1157 1160-1120  44 
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1H-NMR Spectral Study of 2-(4-hydroxyphenyl)-7-[(4-methylphenyl) 
sulfonyl]-1,2,3,5,6,7,8heptahydropyrido[4',3':4,5]thieno [2,3-d]pyrimidin-4-
ones (2d). 
S
N S
O
O
N H
N
H
OH
O
g
a
b
c
d
e
f
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   Instrument: BRUKER 400 MHz (Advance - II), Internal reference: TMS, 
   Solvent: DMSO- d6. 
Serial 
No. 
Signal 
Position  
(δ ppm) 
Relative 
No. of 
Protons 
Multiplicity Inference
1 2.37 3H Singlet -(CH3) a 
2 2.975 2H Broad Singlet -(CH2) b 
3 3.38 2H Triplate -(CH2) c 
4 4.021 1H Singlet -(CH)d 
5 4.349 2H Singlet -(CH2) e 
6 6.948-7.732 8H complex Ar -H 
7 9.77 1H Singlet -(NH) f 
8 12.54 1H Singlet -(OH) g 
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1H-NMR Spectral Study of 2-(3-hydroxyphenyl)-7-[(4-methylphenyl)sulfonyl]-
1,2,3,5,6,7,8heptahydropyrido[4',3':4,5]thieno [2,3-d]pyrimidin-4-ones (2j). 
CH3
S
N S
O
O
NH
N
HO
OH
a
b
c
d
e
f g
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Instrument: BRUKER 400 MHz (Advance - II), Internal reference: TMS, 
Solvent: DMSO- d6. 
Serial 
No. 
Signal 
Position  
(δ ppm) 
Relative No. 
of Protons 
Multiplicity Inferenc
e 
1 2.43 3H Singlet -(CH3) a 
2 3.036-3.049 2H Triplet -(CH2) b 
3 3.433-3.462 2H Triplet -(CH2) c 
4 4.083 1H Singlet -(CH) d 
5 4.410 2H Singlet -(CH2) e 
6 7.008-7.793 8H complex Ar -H 
7 9.83 1H Singlet -(NH) f 
8 12.60 1H Singlet -(OH) g 
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Mass Spectral Study of 2-(4-hydroxyphenyl)-7-[(4-methylphenyl)sulfonyl]-
1,2,3,5,6,7,8heptahydropyrido[4',3':4,5]thieno [2,3-d]pyrimidin-4-ones (2d). 
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Possible Mass Fragmentation pattern: 
m/z= 359
m/z= 455[M+]
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O
O
N
H
NH
O
OH
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+
O
O
NH2
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NH S
NH2
NH2
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NH S
N
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NH
O
OH
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N S
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NH S
N
H
NH
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NO
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N
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NH
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N
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NH
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NH2
+
°
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m/z= 190
m/z= 271
m/z= 335m/z= 279
m/z= 197
m/z= 123
m/z=155
m/z= 279
m/z= 439
base peak
+
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+
°
+
°
°
+
+
°
+
°
+
°
+
°
+
°
+
°
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CONCLUSION 
ANTIMICROBIAL ACTIVITY 
 
 The newly synthesized organic compounds were screened through three 
different types of screening i.e. (1) Primary Screening using 2000 µg/ml conc. (2) 
Secondary Screening 1000 µg/ml to 250 µg/ml conc. (3) Tertiary Screening start from 
125 µg/ml to 3.9 µg/ml. The compounds which were active against the microbes in 
primary screening were taken for the secondary screening. The compounds which 
gave inhibition of microbes in secondary screening were further analyzed in tertiary 
screening. 
 
 From the results of experiments using newly synthesized organic compounds’ 
it is clear that all the compounds were moderately active at lower dilution i.e. high 
concentration like 2000 µg/ml and 1000 µg/ml conc. of compounds. In the series 2a-k 
almost eight compounds 2a, 2c, 2e, 2f, 2g, 2h, 2i and 2k were found active at 500 
µg/ml conc. against staphylococcus aureus. Bacillus Subtilis was inhibited at 500 
µg/ml conc. by seven compounds 2a, 2b, 2c, 2e, 2g, 2i and 2k. Six compounds 2a, 2c, 
2e, 2g, 2i and 2k were active against both cultures B.Subtilis and S.aureus. At the 
conc. 250 µg/ml S.aureus was inhibited by one compound 2k. B.Subtilis was inhibited 
by two compounds 2i and 2k. So, it is obvious from the data obtained that compounds 
2k were highly active among all the compounds of series 2a-k. 
 
 For Gram Negative bacteria in the series 2a-k almost ten compounds 2a, 2b, 
2c, 2d, 2e, 2f, 2g, 2h and 2k were found active at 500 µg/ml conc. against Escherichia 
Coli. S.Paratyphi B. was inhibited at 500 µg/ml conc. by seven compounds i.e.  2a, 
2b, 2e, 2g, 2h, 2i and 2k. So Six compounds were active against both cultures E.Coli 
and S.Paratyphi B. i.e. 2a, 2b, 2e, 2g, 2h and 2k. At the conc. 250 µg/ml E.Coli was 
killed by two compounds 2e and 2k. S.Paratyphi B. was also inhibited by one 
compound   2k. So, it is obvious from the data obtained that compound 2k was highly 
active among all the compounds of series 2a-k. 
 
 For fungi in the series 2a-k almost six compounds 2a, 2c, 2e, 2g, 2i and 2k 
were found active at 500 µg/ml conc. against A.niger. C. albicans was inhibited at 
500 µg/ml conc. by two compounds i.e. 2a and 2k. At the conc. of 250 µg/ml 
C.albicans was killed by one compound 2k.  A. Niger was killed by one compound 2k. 
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So, it is obvious from the data obtained that compound 2k was highly active among 
all the compounds of series 2a-k. 
Tertiory screening for Minimum Inhibitory Concentration: 
(Extensive investigation for the powerful antimicrobials of the series): 
Total nine series of synthesized organic compounds were analyzed for the 
Antibacterial and antifungal activity through primary and secondary screening using 
Agar Dilution Method. To get their exact MIC surprisingly compound 2k (R= 2-OH-
C6H4) of the series were highly active throughout the secondary screening. This one 
compound was highly active and gave complete inhibition of E.Coli, S.Paratyphi B, 
B.Subtilis and S.aureus at conc.250 µg/ml. This compound was highly active at 250 
µg/ml conc. against fungal cultures A.niger and C. albicans. 
Then after this highly active compounds were used for tertiory screening 
against bacterial as well as fungal cultures. Compound 2k (R= 2-OH-C6H4) was 
highly active for E.Coli and S.aureus at 125 µg/ml conc. It was also very effective on 
S.aureus at 62.5 µg/ml conc. 
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SECTION-III 
Preparation, Characterisation and antimicrobial evaluation of Ethyl-2-(3-
arylureido)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydro thieno [2, 3-c] 
pyridine-carboxylates. 
 Keeping in view of wide spectrum biodynamic activities[5-26] of thieno 
pyridine and with a view to have potent therapeutic agents, the synthesis of 
Ethyl-2-(3-arylureido)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydro thieno 
[2, 3-c] pyridine-carboxylates (3a-k) have been synthesized using Ethyl 2-
(phenoxy carbonylamino)-6-[(4-methylphenyl)sulfonyl]-4,5,6,7-tetrahydrothieno[2,3-
c]pyridine-3-carboxylate with differently substituted aromatic amines. 
N
SS
CH3
O
O NH
O
O
NH
O R
CH3
 
(3a-k) 
                                                             R= Aryl 
The constitution of the synthesized products (3a-k) have been 
characterized by using elemental analyses, infrared and 1H nuclear magnetic 
resonance spectroscopy and further supported by mass spectrometry. Purity 
of all compounds has been checked by thin layer chromatography.        
 All the compounds have been evaluated for their antibacterial activity 
against Gram Positive bacteria like Staphylococcus aureus, Bacillus subtilis 
and Gram Negative bacteria like Escherichia coli, Salmonella peratyphi B 
and they were also evaluated for antifungal activity against Candida albicans 
and Aspergillus niger at different concentrations: i.e. Primary screening at 
2000 to 1000, Secondary screening at 1000 to 250 and tertiary screening at 
250 to 3.9 (µg/ml) for their MIC (Minimum Inhibitory Concentration) values. 
The antimicrobial activities of the synthesized compounds (3a-k) have been 
compared with standard drugs. Their antimicrobial effect was determined in 
higher dilution using Agar Dilution Method (Approved by NCCLs). 
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REACTION SCHEME 
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EXPERIMENTAL 
Preparation, Characterization and antimicrobial evaluation of Ethyl-2-(3-
arylureido)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydro thieno [2, 3-c] 
pyridine-carboxylates.  
[A]. Synthesis of Ethyl-2-(3-arylureido)-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7-
tetrahydro thieno [2, 3-c] pyridine-carboxylates (3a-k). 
1.  Synthesis of 1-[(4-methylphenyl) sulfonyl]-4-piperidinone (Intermediate-3). 
In RBF, 4-piperidinone hydrochloride (1.00 mol), THF and Triethylamine (2.5 
mol) were charged. The reaction mixture was cooled to 0°C and 4-methyl phenyl 
sulfonyl chloride (1.05mol) was added portion wise to the reaction mixture at 0°C. 
The reaction mixture was allowed to warm at room temperature and stirred for 4 
hours at same temperature. After the completion of reaction, Reaction mixture was 
concentrated under reduced pressure at 45°C. The crude was quenched with chilled 
water and stirred for thirty minutes. The obtaining solid was filtered and washed with 
water and dried. Yield: 85.00 %. M.P: 131°C, 1H NMR (solvent: CDCl3) δ 7.72 (d, 
2H, J=8.1 Hz), 7.38 (d, 2H, J=8.1 Hz) 3.42 (m, 4H), 2.58 (m, 4H), 2.42 (s, 3H). 
2. Synthesis of ethyl 2-amino-6-[(4-methylphenyl) sulfonyl]-4, 5, 6, 7- Tetra hydro 
thieno [2, 3-c] pyridine-3-carboxylate (Intermediate-4). 
 
In RBF, 1-[(4-methylphenyl) sulfonyl]-4-piperidinone (1.0 mol) (Intermediate-3), 
ethyl cyano acetate (1.10 mol), morpholine (5.0 mol) and sulfur (1.5 mol) was 
dissolved in ethanol at room temperature. The reaction mixture was heated at 70-80°C 
for 3-4 hours. After the completion of reaction, Reaction mixture was concentrated 
under reduced pressure at 45°C. The crude was quenched with chilled water and 
stirred for thirty minutes. The obtained solid was filtered and washed with water and 
dried. Yield: 70.00 %. M.P: 154°C. Elemental Analysis: Calculated: C (53.66%), H 
(5.30%), N (7.36%), Found: C (53.41%), H (5.19%), N (7.22%). 
3. Synthesis of ethyl 6-[(4-methylphenyl)sulfonyl]-2-[(phenoxycarbonyl)amino]-
4,5,6,7-tetrahydrothieno [2,3-c]pyridine-3-carboxylate (Intermeidate-6). 
In RBF, Intermediate-4 (1.0 mol) in THF, pyridine (1.05 mol) were charged at room 
temperature. Into the resulting reaction mixture Phenyl chloroformate (Intermediate-
Thieno Pyridine Derivatives… 
Part-III (Section-III) 
 
181
5) (1.05 mol) was added. The reaction mixture was stirred at room temperature for 2 
hour. After the completion of reaction, Reaction mixture was cool at room 
temperature and concentrated under reduced pressure. The crude was quenched with 
chilled water. The obtained solid was filtered and washed with water and dried. Yield: 
60.00 %. M.P: 142°C. Elemental Analysis: Calculated: C (57.58%), H (4.83%), N 
(5.60%), Found: C (57.30%), H (4.65%), N (5.32%). 
4. Synthesis of Ethyl-2-(3-(4-hydroxyphenyl) ureido)-6-[(4-methylphenyl) 
sulfonyl]-4, 5, 6, 7-tetrahydro thieno [2, 3-c] pyridine-carboxylates (3a-k). 
In RBF, ethyl 6-[(4-methylphenyl) sulfonyl]-2-[(phenoxycarbonyl) amino]-4, 5, 6, 7-
tetrahydrothieno [2,3-c]pyridine-3-carboxylate (1.00 mol) was dissolved in DMSO. 
Triethylamine (2.50 mol) was added to the reaction mixture at room temperature. Into 
the resulting reaction mixture 4-amino phenol was added at room temperature. The 
reaction mixture was stirred for three hours at 60°C. After the completion of reaction, 
reaction mixture was quenched with chilled water. The obtained solid was filtered and 
washed with water and dried. The obtained product was purified by triturating with 
ethanol. Yield: 74.00 %. M.P: 156°C. Elemental Analysis: Calculated: C (55.91%), H 
(4.89%), N (8.15%), Found: C (55.84%), H (4.82%), N (8.09%). 
Similarly, other compounds (3a-k) were synthesized by above mentioned process 
from intermediate: 6. the physical data are recorded in Table-3. 
 
[B]. Antimicrobial activity of Ethyl-2-(3-arylureido)-6-[(4-methylphenyl) 
sulfonyl]-4, 5, 6, 7-tetrahydro thieno [2, 3-c] pyridine-carboxylates (3a-k). 
Antimicrobial activity testing was carried out as described in Part-I, Section-I, Page 
No. (32 to 36) The MIC values of test solution are recorded in Table NO-3a and 3b. 
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TABLE NO-3: Physical constants of Ethyl-2-(3-arylureido)-6-[(4-methylphenyl) 
sulfonyl]-4, 5, 6, 7-tetrahydro thieno [2, 3-c] pyridine-carboxylates (3a-k). 
Sr. 
No. 
Substitution 
R 
Molecular 
Formula/ 
Molecular weight 
M.P. 
°C 
Yield 
% 
% Composition
Calcd./Found 
C H N 
3a  NO
 
C28H32N4O6S2 
584 
184  67 
57.52 
57.44 
5.52 
5.43 
9.58 
9.51 
3b 
O
CH3OCH3  
C26H29N3O7S2 
559 
194  68 
55.80 
55.72 
5.22 
5.17 
7.51 
7.43 
3c  N+
O-
O
F
 
C24H29N4O7S2F 
562 
164  68 
51.24 
51.19 
4.12 
4.08 
9.96 
9.89 
3d 
O
CH3
O
CH3  
C26H29N3O7S2 
559 
194  70 
55.80 
55.72 
5.22 
5.15 
7.51 
7.42 
3e 
CH3
CH3
 
C26H29N3O5S2 
527 
171  71 
59.18 
59.11 
5.54 
5.49 
7.96 
7.89 
3f 
O
O
 
C22H27N3O7S2 
509 
125  74 
51.85 
51.79 
5.34 
5.29 
8.25 
8.21 
3g  OH
 
C24H25N3O6S2 
515 
156  74 
55.91 
55.84 
4.89 
4.82 
8.15 
8.09 
3h 
N+
O-
O
 
C24H24N4O7S2 
544 
202  68 
52.93 
52.85 
4.44 
4.39 
10.29 
10.21 
3i 
OH
CH3  
C25H27N3O6S2 
529 
180  64 
56.69 
56.63 
5.14 
5.08 
7.93 
7.85 
3j 
 
C30H35N3O5S2 
581 
145  68 
61.94 
61.81 
6.06 
6.01 
7.22 
7.17 
3k 
 
C24H25N3O5S2 
499 
153  72 
57.70 
57.64 
5.04 
4.96 
8.41 
8.39 
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IR Spectral Study of Ethyl-2-(3-(4-morpholinophenyl) ureido)-6-[(4-
methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 3-c] pyridine-carboxylates 
(3a).  
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer;  
Frequency range:  4000-400 cm-1 (KBr disc.) 
Type Vibration Mode Frequency in cm-1 Ref. No. 
Observed Reported (Part-1) 
Alkane -CH2 C-H asym. str. 
C-H asym. def. 
C-H sym. Def.  
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44 
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N-H str. (sym.) 
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-C=O str. (Ester) 
3560
3338
1676
1722
3600-3200 
3600-3200 
1740-1650 
1740-1650 
43 
43 
42 
42 
Ether C-O-C assym. Str. 
C-O-C sym. Str. 
1224
1031
1250-1200 
1050-1010 
42 
42 
Sulfonamide N-SO2 1165 1160-1120 44 
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1H-NMR Spectral Study of Ethyl-2-(3-(4-hydroxyphenyl)ureido)-6-[(4-methyl 
phenyl) sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 3-c] pyridine-3-carboxylates (3g). 
S N
S
O
O
O
O
NH
NH
OH
O
ab
cd
e
f
g
h
k
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Instrument: BRUKER 400 MHz (Avance - II), Internal reference: TMS, 
Solvent: DMSO-d6. 
 
 
 
 
 
 
 
 
 
 
 
 
Serial 
No. 
Signal Position  
(δ ppm) 
Relative 
No. of 
Protons 
Multiplicity Inference 
1 1.273 3H Triplet -(CH3) a 
2 2.435 3H Singlet -(CH3) b 
3 2.786 2H Broad singlet -(CH2) c 
4 3.275 2H Triplet -(CH2) d 
5 4.120 2H Singlet -(CH2) e 
6 4.282 2H Quartrate -(CH2) f 
7 6.698-7.705 8H Complex Ar -H 
8 9.19 1H Singlet -(NH) g 
9 9.95 1H Singlet -(NH) h 
10 10.51 1H singlet -(OH) k 
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Mass Spectral Study of Ethyl-2-(3-(4-morpholinophenyl) ureido)-6-[(4-
methylphenyl) sulfonyl]-4, 5, 6, 7-tetrahydrothieno [2, 3-c] pyridine-3-
carboxylates (3a). 
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CONCLUSION 
ANTIMICROBIAL ACTIVITY 
 
 The newly synthesized organic compounds were screened through three 
different types of screening i.e. (1) Primary Screening using 2000 µg/ml conc. (2) 
Secondary Screening 1000 µg/ml to 250 µg/ml conc. (3) Tertiary Screening start from 
125 µg/ml to 3.9µg/ml. The compounds which were active against the microbes in 
primary screening were taken for the secondary screening. The compounds which 
gave inhibition of microbes in secondary screening were further analyzed in tertiary 
screening. 
 
 From the results of experiments using newly synthesized organic compounds’ 
it is clear that all the compounds were moderately active at lower dilution i.e. high 
concentration like 2000 µg/ml and 1000 µg/ml conc. of compounds. In the series 3a-k 
almost three compounds 3a, 3b and 3c were found active at 500 µg/ml conc. against 
staphylococcus aureus. Bacillus Subtilis was inhibited at 500 µg/ml conc. by eight 
compounds 3a, 3b, 3c, 3d,  3f, 3g, 3h, and 3i. Three compounds 3a, 3b and 3c were 
active against both cultures B.Subtilis and S.aureus. At the conc. 250 µg/ml S. aureus 
was inhibited by one compound 3b. B.Subtilis was inhibited by two compounds 3a 
and 3b (3a-k). So, it is obvious from the data obtained that compounds 3b were highly 
active among all the compounds of series 3a-k. 
 
 For Gram Negative bacteria in the series 3a-k almost four compounds 3a, 3b, 
3f and 3i were found active at 500 µg/ml conc. against Escherichia Coli. S.Paratyphi 
B. was inhibited at 500 µg/ml conc. by five compounds i.e.  3a, 3b, 3d, 3f and 3i. So, 
four compounds were active against both cultures E.Coli and S.Paratyphi B. i.e. 3a, 
3b, 3f and 3i. At the conc.250 µg/ml E.Coli was killed by one compound 3a. 
S.Paratyphi B. was also inhibited by two compound 3a and 3b. So, it is obvious from 
the data obtained that compound 3a was highly active among all the compounds of 
series 3a-k. 
 
 For fungi in the series 3a-k almost six compounds 3a, 3b, 3e, 3f, 3h, and 3j 
were found active at 500 µg/ml conc. against A.niger. C. albicans was inhibited at 
500 µg/ml conc. by seven compounds i.e. 3a, 3b, 3e, 3f, 3h, 3i and 3j. At the conc. of 
250 µg/ml C.albicans was not killed by any compounds. A. Niger was killed by one 
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compound i.e. 3f. So it is obvious from the data obtained that compound 3f was 
highly active among all the compounds of series 3a-k. 
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